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Solid solutions enable the fine tuning of crystalline materials’ properties by adjusting 
the composition of their components. They can be applied to several classes of 
materials with a wide range of applications but are difficult to prepare. A general 
guidelines for the preparation of solid solutions were summarised by Hume-Rothery 
(1926) and Kitaigorodsky (1973, 1984). As the use of solid solution in the 
pharmaceutical field is still understudied, the present work describes several research 
themes which consist in the formation of novel solid solutions of APIs. They are 
lithium in salts and in coordination polymers, organic compound (steroids), and metal 
complexes. One of the aims of the present work is to verify the aforementioned 
guidelines of solid solution formations. From this perspective, they are chosen 
compounds that present challenges in their structure to be made as solid solution, 
according to the conventional rules. From the pharmaceutical aspect, solid solutions 
can aid in the preparation of pharmaceutical materials with desirable properties, by 
varying the ratios of components in continuum or at least to a certain extent. The 
successful syntheses of Li/Na mixed salts, Li coordination polymers, and steroid solid 
solutions demonstrate that solid solutions can form amongst non-isostructural 
molecules and pseudo-isomorphous pairs. It is also observed that the existence of 
more stable forms may hinder solid solution formation despite the isomorphous 
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Chapter 1  
Introduction and Background 
 
 
1.1. Crystal Engineering 
 
Crystal engineering is a branch of solid-state chemistry whose goal is to create solid 
crystalline materials by design (Moulton and Zaworotko 2001; Desiraju 2013), which 
have properties suitable for practical applications. Traditionally crystal engineering 
relates to molecular solids and their crystal structures. The increasing demand for new 
materials would ideally benefit from such rational design (Krishnamohan Sharma 
2002; Desiraju 2007; Desiraju 2013).  
R. Pepinsky (1955) first mentioned the term crystal engineering in his work abstract. 
Schmidt then used the term in his work on photodimerization (1971), which states 
that “Rules are now becoming available in what I would regard as phase three, the 
phase of crystal engineering.” Desiraju described crystal engineering as “the 
understanding of intermolecular interactions in the context of crystal packing and the 
utilisation of such understanding in the design of new solids with desired physical and 
chemical properties” (Desiraju 1989; Desiraju et al. 2011). In this view, crystal 
engineering includes the determination of crystal structures, their analysis and 
rationalisation, the design and synthesis of new crystalline material, and finally, the 
study of crystal properties.  
It is understood that different solid forms of a material can possess different 
properties. Hence to modify the properties of crystalline materials, the packing of the 
2 
molecules (i.e. their crystal structure) needs to be accounted for (Schmidt 1971). For 
instance, the utilisation of the metal-ligand coordination bonds for 
noncentrosymmetic solids has enabled the development of nonlinear materials, 
specifically in metal-organic coordination networks where the network assembly 
greatly benefits from the directivity nature of the bonds (Evans and Lin 2002). The 
properties shown by the noncentrosymmetric coordination networks are in favour of 
electrooptic devices application. Similarly, the improvement of the material 
properties, for example solubility of API (active pharmaceutical ingredient), often 
calls for modification of solid forms, such as pharmaceutical salts (Serajuddin 2007), 
polymorphs (Blagden 2001; Censi and Di Martino 2015), and cocrystals (Blagden et 
al. 2007; Duggirala et al. 2014; Duggirala et al. 2016). Indeed, much of the crystal 
engineering activity focuses on the development of pharmaceutical crystals forms 
(Almarsson and Zaworotko 2004), through the exploitation of the hydrogen bonds 
and other weak interactions (Desiraju 1995). Etter and colleagues introduced graph 
sets analysis (Etter et al. 1990), which supports implementation of rational cocrystal 
design (Jones et al. 2006).  Cocrystals are defined as “crystalline single-phase 
materials composed of two or more different molecular and/or ionic compounds 
generally in a stoichiometric ratio which are neither solvates nor simple salts” 
(Aitipamula et al. 2012) as formulated by 46 scientists engaged in the subject. The 
constituents in typical pharmaceutical cocrystals are API and coformers, neutral 
components usually of GRAS (Generally Recognised as Safe) materials (Duggirala et 
al. 2016). In this case, one API can be cocrystallised with different coformers, which 
in turn results in cocrystals with different properties. Pharmaceutical cocrystals can 
have different properties compared to the pure component, for example improved 
bioavailability and stability. Hence, they offers the possibilities for patent application. 
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Several pharmaceutical cocrystals are available on the market, for example 
Depakote™ (ionic cocrystal of divalproex sodium) (Sherman 2000; Petruševski et al. 
2008) and Lexapro™ (ionic cocrystal of escitalopram oxalate) (Harrison et al. 2007). 
Molecular crystalline materials are often subject to a phenomenon called 
polymorphism. The term was used in crystallography in 1822 by Mitscherlich 
(Bernstein 2008). McCrone defined polymorph as “a solid crystalline phase of a 
given compound resulting from the possibility of at least two different arrangements 
of the molecules of that compound in the solid state” (McCrone 1965; Bernstein 
2008).  Polymorphs differ in properties such as solubility, chemical and physical 
stability, and hygroscopicity (Stahly 2007). Pharmaceutical polymorph screening 
(Lee 2014) is important in drug discovery, to select the correct solid forms of API. 
Ritonavir, a compound used in HIV treatment, had already entered the market when 
the second form was discovered (Bauer et al. 2001). Form II of ritonavir is more 
stable and less soluble than form I, which disappeared following the introduction of 
Form II. After reformulation, the drug became available in the market again (Bučar et 
al. 2015). The ritonavir case is one of the notorious cases of disappearing polymorph 
(Bučar et al. 2015). Polymorphism can occur in multi-component crystals too. As 
pharmaceutical cocrystals are researched further, the chance of discovering 
polymorphs of cocrystals increases (Cruz-Cabeza et al. 2015).  
 
 




Figure 1.2. Illustration of cocrystals 
 
As crystal engineering aims to design crystalline materials (Desiraju 2007), it adopts 
some concepts in supramolecular chemistry (Hosseini 2005). The most useful 
strategy is molecular self-assembly (Blake et al. 1999), where the molecules and ions 
act as tectons (building blocks) which are able to “identify” and attach through 
interactions (synthon). However, the discrete nature of atoms and molecules limits the 
modulation of crystal structure and properties in continuum. Within the realm of 
single-component crystals and cocrystals, tuning of materials is possible through 
crystal structure modification. In those cases, the variation of properties tends to be 
discontinuous In the single-component crystals, the alteration or modification of 
crystal structure is limited to polymorphism (Lusi 2018a).  In pharmaceutical 
cocrystals, tuning properties is limited to changing the species of coformers, where 
the discontinuous variation of structures and properties most likely occurs. Unlike 
stoichiometric crystals, solid solutions allow the variation of properties continuously; 
therefore, this can be a strategy to create materials with tuneable properties (Lusi 
2018a; Lusi 2018b).  
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1.2. Solid Solutions  
 
 
Figure 1.3. Solid solutions 
 
1.2.1. History and Terminology 
Van’t Hoff was amongst the first to introduce the term ‘solid solutions’ in the 1890s 
(Van Klooster 1954). Solid solution can be simply described as a solid phase with 
characteristics of a solution (Glasstone 1940) where the solid solute is dissolved in 
the solid solvent. IUPAC defines solid solution as “a crystal containing a second 
constituent which fits into and is distributed in the lattice of the host crystal”, and 
does not recommend the use of solid solution for amorphous materials (IUPAC 
1997). Similar to liquid solutions, the composition of the constituents can be varied 
within a continuum, to a certain extent. The variation of components in a non-
stoichiometric ratio allows to control properties, thus solid solution offers a strategy 
to tune materials properties in a continuous manner.  
Solid solutions have been studied in many fields, including metallurgy, material 
sciences, mineralogy, and chemistry. The pioneering studies on molecular solid 
solutions are discussed in the work of Kitaigorodsky (1984). The other term, mixed 
crystals, can be ambiguous since it can refer to both homogeneous and heterogeneous 
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systems: that is crystals made of different molecules and solids comprised of crystals 
with different structures (Kitaigorodsky 1984). Most silicates and oxides, which 
dominate the minerals on Earth, are solid solutions. Those classes of compounds are 
renowned for being able to incorporate many different elements and are stable at 
extremely large pressures and high temperatures (Geiger 2001). The notion of mixing 
compounds/substances to produce materials with altered properties has been around 
since ancient times, perhaps as far back as the Bronze Age. 
 
1.2.2. Designing a Solid Solution 
Hume-Rothery et al. (1934) studied the formation of solid solutions concerning their 
atom sizes in the metal alloys and ceramic. The empirical principles from Hume-
Rothery (Hume-Rothery 1926) consists of several conditions for solubility. Two 
metals will form a solid solution if: 1) their crystal structures are similar, 2) difference 
of atomic size between the two is not more than 15%, 3) their valences are the same 
(in the same group in the periodic table). In geochemistry, Goldschmidt’s rules of 
substitution are as follows (Goldschmidt 1926): 1) ions will substitute for each other 
in a lattice if their ionic radii difference is not more than 15%, 2) when ions possess 
the same charge but different radii competing for a lattice site, the ion with the 
smaller radius is preferred, 3) when ions possess similar radii but different charges 
competing for a lattice site, the ion with the higher charge is preferred. Ringwood 
(1955) later added the electronegativity factor into the rules; when a substitution is 
possible between elements possessing different electronegativities, the one with 
smaller electronegativity is preferred.  
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Kitaigorodsky (1984) suggested that the geometrical factor is important in solid 
solutions of organic compounds. This geometrical factor can be referred as molecular 
similarity. The similarity of the crystal structure relates to the term isostructurality 
The International Union of Crystallography (IUCr) states that two crystals are 
isostructural if they have the same structure, but not necessarily the same cell 
dimensions nor the same chemical composition, and with a 'comparable' variability in 
the atomic coordinates to that of the cell dimensions and chemical composition 
(Isostructural crystals - Online Dictionary of Crystallography). Two isostructural 
compounds, tetraphenylporphyrin and silver tetraphenylporphyrin are reported to 
form a complete molecular solid solutions series (Donnay and Storm 1967).  There is 
another term that exists to explain about structure similarity, called isomorphous. The 
IUCr states the conditions for two crystals to be isomorphous: 1) have the same space 
group and similar unit cell dimension, and 2) both have the same atoms’ types and 
positions except for a replacement of an atom or more in the other structure, or 
presence of an additional atom or more in one of them (Isomorphous crystals - Online 
Dictionary of Crystallography). Moreover, IUCr also states that isomorphous crystals 
can form solid solutions. Between two compounds that are highly similar, substitution 
of atoms (or groups) is easier provided that the size of the replaced and coming atoms 
(or groups) fits the structure to form solid solutions. Structure flexibility may also be 
a supporting factor, as suggested in the phenazine-acridine system.  
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Figure 1.4. Acridine and phenazine 
 
In the case of solid solutions in phenazine-acridine system, almost complete 
miscibility is observed (Schur et al. 2015) despite the lack of isostructural polymorph. 
This indicates that isostructurality between the parent compound crystal structures is 
not always required, in contrast to what is suggested by Kitaigorodsky (1984). 
Indeed, experimentation might be the best approach to discover the formation.  
From a structural point of view, solid solutions can be classified as interstitial or 
substitutional (Cullity 1978). Substitutional solid solutions occur when a different 
atom, molecule or ion replaces an atom, molecule or ion in the lattice. Interstitial solid 
solutions occur when the different species fill an unoccupied crystallographic position 
in the lattice. Insertion of atoms/ions into the crystal lattice will affect the lattice 
parameters of the crystal. Hence, in solid solutions, lattice parameters will contract or 
expand as the composition of the crystal varies. The relationship between lattice 
parameters and the composition of crystals was postulated by L. Vegard. Vegard’s Law 
(Vegard 1921; Vegard and Dale 1928; Denton and Ashcroft 1991) is an empirical rule 
describing the linear variation of the crystal lattice parameters with the crystal 
composition in solid solutions. The unit cell parameters or lattice parameters can be 
determined by performing an X-ray diffraction. Some deviations from the rule are 
reported (Friedel 1955; Castellanos and West 1980; Schultz and Keller 2014).  Besides 
the mentioned substitution, solid solutions can also form by a mechanism of aliovalent 
or heterovalent substitution. In this case, the replacing species has different charges, 
thus requiring additional changes involving ionic or electronic compensation (West 
1999).     
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Figure 1.5. Illustration of substitutional and interstitial 
 
1.2.3. Phase Diagrams of Solid Solutions 
Solid solutions can be classified according to the miscibility of their components 
(Findlay 1927; Harker 2011), which can be represented using a phase diagram. For 
two components (binary system), the phase diagram can be plotted in two dimensions 
with composition and temperature T as axes x and y respectively. Considering that 
the interest is mostly around atmospheric pressure, and small pressures almost has no 
effect on the phase diagram of solids and liquids, pressure P can be omitted from the 
plot (Ashby and Jones 2013). Ternary systems can be represented with triangular 
phase diagrams, with each point of the triangle represents one component.     
 
Figure 1.6. Phase diagram of (ideal) continuous solid solutions 
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Ideally, the components of the solid solution are mutually miscible in all range of 
composition between the end members, in solid and liquid states. This complete 
solubility results in a continuous series of solid solutions and can be represented with 
phase diagram in Figure 1.6. For instance, binary systems of borneol and camphor 
(Vanstone 1909).  In the binary system of complete miscible solids, maxima and 
minima can be exhibited by the solidus and liquidus curves (Findlay 1927), 
represented by the dash vertical line as phase diagrams shown in the Figure 1.7. 
These maxima and minima are the temperature where the liquid and solid phases of 
the same composition are in equilibrium. In these cases, a series of non-ideal 
continuous solid solutions is formed. 
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Figure 1.7. Series of non-ideal continuous solid solutions. Top: with maximum in the curve. 
Bottom: with minimum in the curve. 
 
Aside from the unbroken, continuous series of solid solutions formed by miscible 
solids, it is also possible that the components do not form continuous series. These 
non-continuous solid solutions are formed by partially soluble solids. Partial 
solubility is the norm in the molecular crystals, whereas complete solubility is rare 
(Lusi 2017). A binary system with this behaviour is represented in Figure 1.8. In this 
case the system exhibits a eutectic or invariant point (point e in the diagram) at 
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temperature Te and composition Ce. Upon cooling at invariant point e, transformation 
of liquid into two solid phases occurs, in this case α and β; upon heating the opposite 
transformation occurs. This is called eutectic reaction. Solvus line is the line that 
separates one solid solution from a mixture of solid solutions. This solvus line shows 
limit of solid solubility (Callister and Rethwisch 2009). α and β represent single solid 
solution phases: α is solid solutions of B in A and β is solid solutions of A in B. 
Within α + β, single phases α and β coexist in all temperature and composition. This 
phase diagram has three single-phase regions (Liquid, solid solutions α and β) and 
three two-phase regions (α + β, α + Liquid, and β + Liquid). 
 
Figure 1.8. Phase diagram of binary system of non-continuous solid solutions 
 
In the other case of partially miscible solids that do not form continuous solid 
solutions, freezing-point curve (liquidus curve) can exhibits a transition point 
(Findlay 1927), as shown in Figure 1.9 point C. Under the melting-point curve, two 
different solid solutions can be existed. Here, the solidus curve is separated into A’D 
and B’E, with DE as the break of the solid solution series. The transition in point C is 
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at equilibrium with points D and E, which represent the two solid solutions: enriched 
B in A (point D) and enriched A in B (point E).     
 
Figure 1.9. Phase diagram of binary system with transition point 
 
 
Two components in a binary system that are completely miscible in liquid state can 
separate into two solids as the temperature gets lower and solidification occurs. Here 
the components are non-miscible at solid state and can be represented in phase 
diagram as Figure 1.10. Solid solutions do not exist in this condition. Below the 
solidus line, only solid components or mixture of components presents. Eutectic is 




Figure 1.10. Phase diagram of binary components non-miscible in solid state 
 
Cooling of molten components can produce eutectic materials instead of solid 
solutions. Eutectic material can obtained by cooling a eutectic system at the eutectic 
point, creating a non-homogeneous solid, a kind of composite (Cherukuvada and 
Nangia 2014). Due to their heterogeneous nature, eutectic materials are challenging to 
characterise by X-ray diffraction (Cherukuvada and Guru Row 2014; Cherukuvada 
and Nangia 2014). Eutectic systems have been studied as an approach to improve 
physicochemical properties in pharmaceuticals such as urea-acetaminophen system 
(Goldberg et al. 1966a), chloramphinecol-urea eutectic (Goldberg et al. 1966c), and 
griseofulvin-succinic acid system (Goldberg et al. 1966b) where eutectic mixture is 




Solid solutions can be produced as crystals through several crystallisation methods, or 
as microcrystalline powder through solid-state synthesis. Mixing the reactants in a 
solution followed by the slow evaporation of the solvent yields crystals, such as solid 
solutions of antiretroviral drugs lamivudine and emtricitabine (Fonseca et al. 2018) 
and in thermosalient complex (Nauha et al. 2016). Shemchuk et al. (2016) pointed 
out that during crystallisation, the choice of solvent can affect the formation of solid 
solutions, where barbituric acid and thiobarbituric acid form solid solutions with 
ethanol used in crystallisation, but not with more polar solvents like methanol. 
Melting the reactants and allowing the melts to cool down can also obtain solid 
solutions, as demonstrated in binary and ternary solid solutions of p-
methyl/chloro/bromo-benzyl alcohols (Romasanta et al. 2017). 
In solid-state chemistry, mechanochemical synthesis is popular for being a green 
process due to the small amount of solvent used (or in some cases, solvent-free) 
(James et al. 2012), hence less waste. This type of synthesis utilises mechanical 
energy to induce a chemical reaction (IUPAC 1997), such as grinding the reactants 
together in a ball milling with a milling jar, or manually with a mortar and pestle. The 
reaction can either be dry (by simply grinding the solid reactants, termed as neat 
grinding) or wet (liquid-assisted grinding, solvent-assisted grinding, or kneading). In 
the latter, solvent (liquid) is involved in the reaction. Nevertheless, Braga and 
colleagues state that “kneading” denotes the process of grinding one, two, or more 
components together deliberately with small amounts of liquid, whilst “liquid-
assisted grinding” generally includes reactions occurring through the intervention of a 
liquid phase whether the liquid is an intentional addition or is present at some stage 
during the process (Braga et al. 2013). Bowmaker proposed a mechanism whereby 
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the addition of a small amount of liquid serves as a solvent for one or more solid 
reactants, allowing for transport through an intermediate phase, by either convection 
or diffusion (Bowmaker 2013). Mechanochemistry offers an approach to inaccessible 
reactions in a solution environment in the case of poorly soluble reactants. For 
example, cocrystals of reactants with different solubilities in solvents may be difficult 
to crystallise using solution methods, such as cocrystals of lithium chloride and 
cyanuric acid (LiCl∙CA) (Shemchuk et al. 2017) where its crystal structure is solved 
using powder X-ray diffraction. Grinding reactants at low temperature (cryogenic 
cogrinding) can produce amorphous materials, which can convert into crystalline 
phase during storage (Jayasankar et al. 2006) as demonstrated in cocrystal 
carbamazepine-saccharine. Mechanochemistry uses minimum to zero amounts of 
solvent and employs mechanical energy to drive the reaction to completion.  
Mechanochemical methods have been reported to yield solid solutions, such as in 
mixed-metals (Adams et al. 2010a), salts (Adams et al. 2010b), coordination 
polymers (Lusi et al. 2011), metal organic framework (Adams et al. 2010b), and in 
cocrystal solid solutions (Cruz-Cabeza et al. 2018; Paul et al. 2018). As the product 
of mechanochemical methods is in microcrystalline powder form, the characterisation 
by X-ray diffraction is limited to powder X-ray diffraction (PXRD). If good quality 
single crystals can be obtained from the crystallisation of the powder samples, then 
single crystal X-ray diffraction (SCXRD) can be performed.  
Supercritical fluid (SCF) can be an alternative as a means of synthesis. Synthesis 
under supercritical condition has been reported for solid solutions of anthracene and 
phenanthrene (Liu and Nagahama 1997) as well as of barium strontium titanate, a 
ceramic that can be utilised for tunable resonators, filters, phase-shifters, variable-
powder dividers and variable frequency oscillators (Reverón et al. 2006). IUPAC 
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describes supercritical fluid (SCF) as a phase above its critical pressure (pc) and 
critical temperature (Tc) (IUPAC 1997). Jessop and Leitner (2008) emphasised that 
this definition include states of pressure below the one required to condense it into a 
solid. Supercritical fluids have been developed for applications in industrial 
processes, including pharmaceuticals (Fages et al. 2004; Knez et al. 2014; Padrela et 
al. 2018). The most common supercritical fluid is supercritical carbon dioxide 
(scCO2); its use is favoured due to its health and safety benefits (it is non-
carcinogenic, non-toxic, non-mutagenic, non-flammable, and thermodynamically 
stable) (Knez et al. 2014) and its physicochemical property-tunable behaviour, as 
well as being “green” (that is sustainable, safe, and environmentally friendly) 
(Padrela et al. 2018). There are several methods of exploiting supercritical fluids in 
crystallisation; for example RESS (rapid expansion of supercritical solutions) and 
SAS (supercritical antisolvent) and GAS (gas antisolvent). In the GAS method, the 
supercritical fluid functions as antisolvent. The solutes are dissolved in the SCF 
solvent miscible. The introduction of SCF into the solution creates supersaturation in 
the solution, which leads to precipitation of the solid forms. Unlike GAS, SAS 
method involved atomisation by the usage of nozzle similar to the RESS processes 
(Chakravarty et al. 2019). In the SAS method, the solutes are dissolved in the organic 
solvent, whereas in RESS methods the solutes are dissolved in the SCF. Therefore, 
SAS is an alternative process for the compounds that are not soluble in the SCF. 
Upon the pumping of supercritical fluid to the precipitation chamber, it meets the 
liquid solution of compounds in the organic solvent. The supercritical fluid then 
dissolves into the liquid, leaving precipitations of solutes in small particles 




Depending on the material type and properties of interest, the appropriate 
characterisation methods can be chosen. X-ray diffraction is a great tool in 
crystallography, since it enables one to ‘see’ the internal structure of crystals. 
Crystallography gets a major breakthrough following the discovery of X-ray by 
Wilhelm Röntgen. Max von Laue and his colleagues’ work in 1912 revealed that 
crystals could diffract X rays. This discovery led the Braggs (W. H. Bragg and W. L. 
Bragg) to use X rays in order to analyse the structure of crystals; the Nobel Prize in 
1915 was awarded to them for this work. It was W. L. Bragg, the son, who 
formulated the Bragg’s equation that became very fundamental for in the 
crystallography. Crystal structure can be solved from diffraction patterns. Electrons 
of atoms in a crystal lattice scatter X rays. The constructive interference of the 
diffracted X rays generates a regular series of intensities that compose ‘spots’ or 
‘reflections’ in what is called diffraction pattern or diffractogram.  
 





Figure 1.12. X-ray diffraction schematic for single crystal and powder samples  
 
If single crystals are available, single crystal X-ray diffraction (SCXRD) can be 
performed. SCXRD can determine the structures of the crystals, chemical (atomic) 
compositions/quantification by site occupancy factor (s.o.f), as well as unit cell 
parameters of the crystals. This way, it is possible to view the three-dimensional 
structures of the studied compound (crystals). X-ray crystallography fulfils these 
conditions: 1) the type of atoms are distinguishable, 2) the position of the individual 
atom inside the molecule can be determined, 3) the view of molecules from as many 
different directions as possible can be obtained, as well as the relative position among 
the molecules from a different view can be determined precisely (Hasegawa 2012). 
The single crystal is placed in the X-ray where the diffraction spots of the crystals are 
recorded. The structure solution and structure refinement follow once the data 
collection is completed. From this, structural model from the studied compound is 
obtained. The crystal structures obtained from experiments can be deposited into 
databases such as the Cambridge Structural Database (CSD) (Groom et al. 2016) and 
Inorganic Crystal Structure Database (ICSD) (Belsky et al. 2002). However, it is 
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rather challenging to locate the hydrogen atoms from the X-ray diffraction data 
precisely. For crystalline solid solution, structure refinement corresponds with that of 
a disorder crystal, where partial atomic occupancy is possible. Crystallographic 
analysis of solid solutions can be hindered by the presence of a component that break 
the crystal symmetry (Lusi 2017), for example, substitution of a high symmetry 
molecule with a less symmetrical one will result in the loss of symmetry.  
 
  
Figure 1.13. Crystal structure determination outline from single crystal diffraction 
 
The products of mechanochemical synthesis are usually in microcrystalline form, 
which can be analysed by powder diffraction. This can be done in many ways: using 
common laboratory PXRD equipment, synchrotron facility, neutron, or electron 
sources.  PXRD is useful as it produces fingerprint to identify crystalline materials. In 
mixtures, PXRD analysis can be used in quantitative analysis to determine the phase 
composition of the samples, for example, by performing Rietveld refinement 
(Rietveld 1969; McCusker et al. 1999). Moreover, PXRD can confirm the 
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homogeneity and the purity of the bulk samples by comparing it to the calculated 
powder pattern from the SCXRD data. In cases where single crystals could not be 
obtained, PXRD patterns can be used to solve the crystal structure, as well as to 
obtain the unit cell parameters as long as the data is of sufficient quality. Technically, 
the best data can be obtained from a synchrotron. In the laboratory setting, ideally, the 
data are obtained from samples in rotating capillary with transmission geometry using 
monochromatic Cu Kα1. The conditions must be met to optimise the solving of 
crystal structures successfully: accurate measurement of reflection positions and 
intensities, high angular resolution and spatial resolution, good signal-to-background 
ratios across the full pattern and minimal preferred orientation effects (Florence et al. 
2005). The challenge of solving crystal structures from powder diffraction patterns is 
the substantial loss of information after the three dimensions of reciprocal space are 
collapsed into the single dimension of powder diffraction (David and Shankland 
2008). The process of structure determination from powder diffraction can be 
simply imagined as a maze (David et al. 2006), although it may be varied case by 
case. The process starts with determining the best radiation source available or 
feasible for data collection. The diffraction pattern obtained then can be indexed 
and followed by space group determination. The next procedures are profile 
decomposition and intensity extraction, which can be done by performing the 
least-square method (Pawley 1981) or an iterative approach (Le Bail et al. 1988). 
Afterwards, structure solution and model optimisation can be performed and 
followed by Rietveld refinement (Rietveld 1969; Young 1993) of the structure.  
Thermal characterisation of a material can be done by thermogravimetric analysis 
(TGA) and differential scanning calorimetry (DSC). TGA measures the weight loss 
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or gain in the sample as a function of temperature. In the TG analyser, the sample is 
subjected to heat at a certain rate to a certain temperature point while its weight is 
being measured. Decomposition temperature can be determined by TGA. DSC 
measures the differences in heat flow in the sample and reference pans when they are 
heated, cooled, or in isothermal conditions along with the temperatures. The 
thermogram from the measurement can exhibit an endothermic process, which occurs 
when heat is absorbed by the sample in an event such as melting or water/solvate 
loss. An exothermic event emerges when heat is released as in crystallisation or 
crystal structure rearrangement. Hence, DSC can help to determine the melting, 
polymorphism, as well as the purity of the solids under examination.   
Dynamic vapour sorption (DVS) is a gravimetric analysis that measures how much 
solvent, generally water, can be absorbed by a sample. Exposure to moisture or 
humidity can trigger phase transition on certain materials. This is challenging since 
phase transition may result in different properties. In this case, DVS measures the 
water uptake, thus hydrate formation/loss can be quantified. In the DVS apparatus, 
the sample is subjected to a different relative humidity (RH) level or water vapour 
pressure whilst the temperature can be kept constant (isotherm). For pharmaceuticals, 
high stability to humidity variation is critical to guarantee the product’s safe storage 
over a prolonged time. European Pharmacopoeia (2013) categorised the 
hygroscopicity of samples based on the percentage increase in sample mass at 
25 ± 1 °C and 80 ± 2% RH. It is deliquescent if it absorbs enough water to form a 
liquid. If the mass increase is equal to or greater than 15%, it is very hygroscopic. 
When the increase is between less than 15% and equal to or greater than 2%, it is 
hygroscopic. For an increase between less than 2% and equal to or greater than 0.2%, 
it is slightly hygroscopic.   
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Other characterisations such as scanning electron microscope (SEM), and 
transmission electron microscope (TEM) can help with chemical analysis when 
equipped with energy dispersive X-ray spectroscopy (EDX, EDS) or electron energy 
loss spectroscopy (EELS). TEM and SEM can be used in electron diffraction to 
obtain crystallographic information. SEM can observe the microstructure and 
morphology of the solid solution samples. Particle sizes of microcrystalline powder 
may be analysed as well. For pharmaceutical interest, solubility of materials can be 
studied with UV and HPLC method. 
 
1.2.6. Examples and Applications of Solid Solutions  
Considering of the range of material and possible resulting properties, this approach 
is quite general. From a pharmaceutical perspective, solid solutions offer controls 
over physicochemical properties, such as physical and chemical stability, and 
hygroscopicity. In some cases, solid solutions have properties that differ significantly 
from those of pure components (Geiger 2001). In the pharmaceutical context, solid 
solution has been investigated as a mean to improve the physicochemical properties. 
Some patents that included the term “solid solution” have been registered such as for 
hormone therapy: solid solution of steroid API (progesterone, testosterone) with 
steroidal lipids (cholesterol, cholesterol acetate, β-sitosterol) (Rudel 1974a), and solid 
solution of steroid hormone (progesterone) with lipids carrier (cholesterol) (Rudel 
1974b), in this view, the preparation of solid solutions might represent a strategy to 
increase the dissolution rate and gastrointestinal absorption of the drug product, as 
demonstrated by the griseofulvin – succinic acid system (Goldberg et al. 1966b), and 
chloramphenicol – urea system (Goldberg et al. 1966c). Cytosine, one of the main 
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bases found in DNA and RNA, and 5-flucytosine, a derivative of cytosine and an 
antifungal medication, formed a monohydrate solid solution, but only with the 
presence of more than 20% of 5-flucytosine (Braun et al. 2017). The solid solution 
reported has increased thermal- and moisture stability compared to 5-flucytosine 
alone. The antiretroviral drugs lamivudine and emtricitabine (FTC) formed a solid 
solution of 3TCH:xFTC with an altered melting point due to the concentration of FTC 
(Fonseca et al. 2018). (±)4′-methylmethcathinone solid solution, formed from its 
hydrochloride and hydrobromide salts, was used as a model in a study of solid 
solution to control the phase transition temperature and melting point (Delori et al. 
2014), although this study is not meant to improve its drug model as it is currently 
banned in several countries.     
Cocrystal solid solutions can be imagined as two cocrystals mixed together, for 
example isonicotinamide2:[fumaric acid(x)succinic acid(1-x)] (IN2:[FA(x)SA(1-x)]1), 
where 0 ≥ x ≥ 1. This solid solution is prepared by combining cocrystals 
isonicotinamide:fumaric acid (IN2:FA1) and isonicotinamide:succinic acid (IN2:SA1) 
which are isostructurally related (Oliveira et al. 2008). Another example is a ternary 
cocrystal solid solution (res)∙(Cl-PE)(x)∙(Me-PE)(2-x) (x ≈ 1), where res is a template 
molecule based on resorcinol, Cl-PE is 
trans-1-(4-chlorophenyl)-2-(4-pyridyl)ethylene, Me-PE is 
trans-1-(4-methylphenyl)-2-(4-pyridyl)ethylene. This is used as an approach for 
cross-photodimerisation reaction in a solid state, where it was not possible with two-
component solid solutions of the olefins in the absence of the res template (Bučar et 
al. 2012). Cocrystalline solid solutions can create higher order multicomponent 
crystalline solid, such as three-component solid solutions {Li2(suc)x(mal)y(met)z}n 
where (suc) is succinate, (mal) is malate, and (met) is methylsuccinate, x + y + z = 1 
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(Yeung et al. 2013), and five- and six-component crystalline solids recently reported 
(Paul et al. 2018). 
Solid solutions of enantiomers are discussed by Chion and colleagues (1978) and the 
types were further reviewed by Rekis and Bērziņš (2018).  Rekis and Bērziņš have 
identified two types of structure. In type 1, enantiomers are interchangeable in the 
crystal structure. In type 2, the enantiomers are recognised as different entities by the 
crystal and sit in crystallographic enantioselective positions. In optically active drugs, 
enantiomers have different properties and their separation is important. The formation 
of enantiomer solid solution hinders optical resolution (de Diego et al. 2011).  
In the broader context, solid solutions have been studied for technology-relevant 
applications also, and in many classes of materials. Such as conductivity and 
thermophysical properties (Huang et al. 1997), optical properties (Mancini et al. 
2015), temperature of phase transition and melting point of a drug (Delori et al. 
2014).  Solid solutions were also studied for rechargeable batteries, for instance to 
make cathode material (Moshtev et al. 1995). Ceria-zirconia solid solution is known 
to function as oxygen storage material and is exploited in automotive application 
(Ozawa et al. 1993; Sugiura 2003). In porous coordination polymers, studies were 
done for modifying gas adsorption properties (Fukushima et al. 2010) and gas 
separation (Horike et al. 2012) application. In a metal organic framework, mixing the 
metal composition of nickel and cobalt could adjust the magnetic behaviour of the 
material (Zeng et al. 2006). Noncentrosymmetric (NCS) crystal structures attract 
interests for technological applications that utilised their nonlinear optical properties. 
Second harmonic generation (SHG) responses in several NCS solid solutions have 
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been investigated, such as in polar aluminoborates Al5−xGaxBO9 (0.0 ≤ x ≤ 0.5) where 
the SHG increases as more Ga is added (Jo et al. 2017).   
 
1.3. Research Objectives 
 
From a pharmaceutical perspective, solid solutions can aid the preparation of drugs 
with desirable properties, by varying the ratio of components in a continuum. In order 
to study the pharmaceutical solid solutions, the first step is making solid form easily 
accessible. Unfortunately, solid solutions are rarely investigated compared to other 
types of solid forms. Hume-Rothery rules (Hume-Rothery et al. 1934) and the 
concept of isostructurality from Kitaigorodsky (Kitaigorodsky 1984) can serve as a 
general guideline for obtaining solid solutions. The issue is whether the rules 
suggested by Hume-Rothery and the concept proposed by Kitaigorodsky always 
govern the formation of solid solution. The acridine-phenazine system (Schur et al. 
2015) suggests that such guidelines might sometimes be too strict. Hence, solid 
solution hypothetically can be formed, regardless of the Hume-Rothery rules and 
isostructurality concept. Therefore, the objectives of the study are: 
1. To verify Hume-Rothery rules and Kitaigorodsky’s suggestion on forming 
solid solutions.  
2. To verify the efficient method of preparing solid solutions. 
3. To evaluate the potential of solid solutions as drug materials.  
The following chapters will discuss several experiments with different types of APIs 
(salts, coordination polymers, organic compound (steroids), and metal complex) to be 
made into solid solutions. Moreover, an effort is made to tackle specific issues known 
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for the target drugs. Lithium will be studied with different anions and as coordination 
polymers (Figure 1.15), since different crystal forms can result in different properties. 
Finally, a throughout characterisation techniques will be employed to relate the 
properties of the solid solutions with those of the pure components.  
 




Figure 1.15. Experimental scheme for lithium studies 
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The first API is lithium, where it will be studied in the salt and coordination polymer 
forms. Chapter 2 will discuss the salt form of lithium, in which three different anions 
will be investigated: citrate, isoorotate, and orotate. In these systems, the composition 
of lithium will be varied with sodium.  
In Chapter 3, the ligand composition of the lithium coordination polymers will be 
varied to form solid solutions. The first one is an attempt to form solid solutions 
{Li[MBNZ]x[BNZ]1-xPro}n  from two lithium coordination polymers (Zaworotko et 
al. 2017) {Li[BNZ]Pro}n and {Li[MBNZ]Pro}n where MBNZ = 2-methoxybenzoate, 
BNZ = benzoate, Pro = L-Proline, 0 ≤ x ≤ 1. The second one is to form 
{Li2[SUC]x[MAL]1-x}n where SUC = succinate, MAL = malate, 0 ≤ x ≤ 1 from 
{Li2[SUC]}n and {Li2[MAL]}n coordination polymers, which previously was 
reported to form binary and ternary solid solutions (Yeung et al. 2013).  
Chapter 4 involves the steroid hormones. The study aims to investigate whether solid 
solutions can be formed between cortisone and hydrocortisone, whose structures are 
non-isostructural. This would be a representation of a drug-prodrug solid solution.  
The metal complex cisplatin (cis-[Pt(NH3)2Cl2]), a chemotherapy drug, is discussed 
in Chapter 5. The aim is to investigate if solid solution of cisplatin with its analogues 
is possible, such as cis-[M(NH3)2ClxBr1-x] where M = Pt or Pd, and cis-[ PtxPd1-
x(NH3)2X2] where X = Cl, Br or I and 0 ≤ x ≤ 1. Finally, the results of this work will 





Chapter 2  
Lithium Salts1  
 
2.1. Introduction 
The first API as the model considered in this study is lithium, a cation combined into 
molecular salt. Lithium has been used in mood disorder treatment, particularly for 
bipolar disorder. Numerous investigations were made on lithium for years, and 
finally, in 1974, the FDA approved its usage for treatment of bipolar disorder (Schou 
2001). The World Health Organization also lists lithium carbonate as an essential 
medicine. Lithium can be used in prophylactic treatment and regarded as highly 
efficacious in typical bipolar manic-depressive illness. There is a suggestion for 
lithium to be the preferred prophylactic drug for patients with high suicidal risk 
following its effect in reducing suicidal behaviour. Lithium salts approved by the 
FDA for medication purpose are lithium carbonate and lithium citrate. Lithium 
carbonate is administered orally in tablet form with doses around 0.4 – 2.0 g/day, 
dependent on renal function and use of other drugs (Oruch et al. 2014). Lithium 
citrate is available in tablet and syrup forms. There is also lithium orotate that is 
available without prescription (Lakhan and Vieira 2008) and marketed as a 
supplement (Pauzé and Brooks 2007).  
                                                            
1  Most part of this chapter appears in  
Lestari, M. and Lusi, M. (2019) 'A mixed molecular salt of lithium and sodium breaks 
the Hume-Rothery rules for solid solutions', Chemical Communications, 55(16), 
2297-2300, available: http://dx.doi.org/10.1039/C8CC09850F. 
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The known common side effects of lithium usage are numerous. For instance, in the 
gastrointestinal system, it causes nausea, thirst or a dry mouth, metallic taste, 
vomiting, and diarrhoea (Maletzky and Shore 1978). Fatal poisoning can happen in 
humans with 5 g of lithium chloride. In psychiatry, the required lithium carbonate 
dose is close to the maximum safe level. In simple words, the therapeutic window of 
lithium dose is extremely narrow. Normal therapeutic serum concentration of lithium 
is about 5.6 – 8.4 mg/L, whereas at about 10.5 – 17.5 mg/L it can lead to mild 
toxicity, 17.5 – 24.5 mg/L moderate toxicity, and > 24.5 mg/L severe symptoms can 
manifest (Aral and Vecchio-Sadus 2008). This narrow therapeutic/toxic ratio limits 
the prescription of lithium exclusively to centres with available means to measure and 
monitor serum concentrations (Oruch et al. 2014).  The known side effects and the 
desirable effects of lithium treatment can be balanced with individual doses fine-
tuning and serum lithium concentrations, and intoxication can be thwarted with 
precautionary guidelines (Schou 2001).  
The risks for side effects and possible toxicity have led to many investigations aimed 
at improving the lithium safety and clinical performance. Some products are in the 
form of coordination polymers and ionic cocrystals (ICC), such as piracetam with 
lithium bromide and lithium chloride (Braga et al. 2012), α-D glucose with lithium 
bromide and lithium chloride (Duggirala et al. 2014), lithium salicylate and L-proline 
(Smith et al. 2013; Duggirala et al. 2016) and lithium hydroxide with nicotinic acid 
and L-proline (Smith et al. 2013). A lithium complex in the form of monoaqua 
lithium isoorotate has been reported (Wagner et al. 1999). There are several proposed 
mechanisms of lithium action for bipolar disorder (Marmol 2008; Oruch et al. 2014). 
Lithium can get into the cells by substituting sodium or potassium on transport 
proteins (Timmer and Sands 1999) and excreted by the kidney where in the proximal 
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tubule it is processed comparably likewise to sodium (Okusa and Crystal 1994). 
However, sodium deficiency can be linked to an increased risk of lithium intoxication 
due to reabsorption of lithium (Bennett 1997). Hence, having an optimal ratio of 
sodium and lithium can be beneficial as to diminish the toxicity. 
In this chapter, potential solid solutions of Li are targeted. The API, lithium cation 
(Li+) is combined with sodium cation (Na+), and their ratio is varied. Lithium and 
sodium are on the same group in the periodic table (alkali metals), and their ions have 
the same charge. However, Li and Na differ in sizes. Their van der Waals radii are 
1.82 Å and 2.27 Å, respectively (Bondi 1964). The ionic form of citric acid, orotic 
acid and isoorotic acid is selected for the solid solutions attempt since lithium citrate 
and lithium orotate are available on the market, and the potential of lithium isoorotate 
monohydrate has been reported (Wagner et al. 1999). Citric acid can form ions 
C6H5O7-3 (citrate), C6H6O7-2 (hydrogen citrate), and C6H7O7- (dihydrogen citrate). 
Looking at the reported crystal structures in Cambridge Structural Database (CSD) 
(Groom et al. 2016), lithium citrate can crystallise in several forms: trilithium citrate 
pentahydrate (Li3C6H5O7·5H2O, CSD refcode CADJIA (Rossi et al. 1983)), trilithium 
citrate tetrahydrate (Li3C6H5O7·4H2O, FUQFUS (Schreuer and Haussühl 2000)), 
trilithium citrate dihydrate (Li3C6H5O7·2H2O, ZZZIZG (Love and Patterson 1960)), 
and lithium dihydrogen citrate (LiC6H7O7, LIHCIT (Glusker et al. 1965)).  The 
sodium counterpart exists as trisodium citrate pentahydrate (Na3C6H5O7·5H2O, 
ZZZRCO (Burns and Iball 1954)), trisodium citrate dihydrate (Na3C6H5O7·2H2O, 
UMOGAE (Fischer and Palladino 2003)), trisodium citrate pentahemihydrate 
(Na3C6H5O7·5.5H2O, FATTID (Voissat et al. 1986)), and sodium dihydrogen citrate 
(NaC6H7O7, NAHCIT (Glusker et al. 1965)). Among these structures, the dihydrogen 
citrates of Li and Na constitute an isomorphous pair (CSD refcodes LIHCIT and 
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NAHCIT) (Glusker et al. 1965). The others are not isostructural. For the orotate ion, 
the lithium salt has been reported (LiC5H3N2O4·H2O, SIMZOD (Bach et al. 1990), 
SIMZOD01 (Lutz 2001)), but no report of sodium salts are known. The isoorotate 
compounds exist with both lithium (LiC5H3N2O4·H2O, VEYVUQ (Wagner et al. 
1999)) and sodium (NaC5H3N2O4·H2O, ACUFIO (Nichol and Clegg 2006)). They 
exhibit a phenomenon called pseudo-isomorphism (Chao and McCullough 1961; 
d’Agostino et al. 2014) where crystal isomorphism occurs despite differs in the 
chemical arrangements. Hence, isoorotate (IOR), dihydrogen citrate (H2CIT), and 
orotate (ORO) will be used in the attempt of solid solutions with various ratio of Li 




Figure 2.1. Anions and cations used in the experiments 
 
2.2. Experimental  
2.2.1. Isoorotate 
Lithium carbonate and sodium carbonate were purchased from Sigma Aldrich while 
isoorotic acid were purchased from Acros Organics. The starting materials were used 
without further purification. The samples were all produced by standard 
mechanochemical procedures whereby the amount of starting materials according to 
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the ratio were placed in an agate mortar and pestle and ground with the aid of 
necessary solvent.  
 
Synthesis of Li1-xNaxIOR·H2O (1x) where 0 ≥ x ≥ 1 
LiIOR·H2O (10): 0.50 mmol (37.0 mg) of Li2CO3 and 1.00 mmol (156.1 mg) of 
isoorotic acid were placed into a mortar with 80 μL of DI water and ground for 10 
minutes. 40 μL of DI water was added before further ground for 10 - 15 minutes until 
dry.   
Li0.7Na0.3IOR·H2O (10.3): 0.35 mmol (25.9 mg) of Li2CO3, 0.15 mmol (15.9 mg) of 
Na2CO3, and 1.00 mmol (156.1 mg) of isoorotic acid were placed into a mortar with 
80 μL of DI water and ground for 10 minutes. 60 μL of DI water was added before 
further ground for 10 - 15 minutes until dry. 
Li0.5Na0.5IOR·H2O (10.5): 0.25 mmol (18.5 mg) of Li2CO3, 0.25 mmol (26.5 mg) of 
Na2CO3, and 1.00 mmol (156.1 mg) of isoorotic acid were placed into a mortar with 
80 μL of DI water and ground for 10 minutes. 60 μL of DI water was added before 
further ground for 10 - 15 minutes until dry. 
Li0.3Na0.7IOR·H2O (10.7): 0.15 mmol (11.1 mg) of Li2CO3, 0.35 mmol (37.1 mg) of 
Na2CO3, and 1.00 mmol (156.1 mg) of isoorotic acid were placed into a mortar with 
80 μL of DI water and ground for 10 minutes. 60 μL of DI water was added before 
further ground for 10 - 15 minutes until dry. 
NaIOR·H2O (11): 0.50 mmol (53.0 mg) of Na2CO3, and 1.00 mmol (156.1 mg) of 
isoorotic acid were placed into a mortar with 80 μL of DI water and ground for 10 




2 – 3 mg of each sample (1x) was dissolved in 1.5 ml DI water and sonicated for 15 
mins at 60 °C. The solution then was transferred into watch glass covered with 
parafilm with several holes. Crystals appeared after a few days. Suitable crystals were 
measured by single crystal XRD. The data for the crystals are in Table 2.1. 
 
2.2.2. Dihydrogen Citrate 
Lithium carbonate, sodium carbonate, sodium bicarbonate, and citric acid (Sigma 
Aldrich) were used without further purification. The samples were all produced by 
standard mechanochemical procedures whereby the amount of starting materials 
according to the ratio were placed in an agate mortar and pestle and ground with the 
aid of necessary solvent. 
 
Synthesis of Li1-xNaxH2CIT (Mix 2x) where 0 ≥ x ≥ 1 
LiH2CIT (Mix 20): 2.0 mmol (148 mg) Li2CO3 and 4.0 mmol (768.8mg) citric acid 
were placed into a mortar and around 11 drops of ethanol with a Pasteur pipette to 
make a paste-like consistency. The paste was ground and added with a few drops of 
water before grinding again until dry. PXRD and TGA confirmed the product to be 
the monohydrate. The anhydrous form was obtained after heating in the oven at 
100 °C. 
Li0.9Na0.1H2CIT (Mix 20.1): 1.8 mmol (133.3 mg) Li2CO3, 0.2 mmol (21.3 mg) 
Na2CO3, and 4.0 mmol (768.5mg) citric acid were placed into a mortar and around 14 
drops of ethanol with a Pasteur pipette to make a paste-like consistency. The paste 
was ground and added with a few drops of water before grinding again until dry.  
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Li0.7Na0.3H2CIT (Mix 20.3): 1.4 mmol (103.6 mg) Li2CO3, 0.6 mmol (63.7 mg) 
Na2CO3, and 4.0 mmol (768.7mg) citric acid were placed into a mortar and around 14 
drops of ethanol with a Pasteur pipette to make a paste-like consistency. The paste 
was ground and added with a few drops of water before grinding again until dry.  
Li0.5Na0.5H2CIT (Mix 20.5): 1.0 mmol (73.9 mg) Li2CO3, 1.0 mmol (106.1 mg) 
Na2CO3, and 4.0 mmol (768.8mg) citric acid were placed into a mortar and around 14 
drops of ethanol with a Pasteur pipette to make a paste-like consistency. The paste 
was ground and added with a few drops of water before grinding again until dry.  
Li0.3Na0.7H2CIT (Mix 20.7): 0.6 mmol (44.6 mg) Li2CO3, 1.4 mmol (148.7 mg) 
Na2CO3, and 4.0 mmol (768.6mg) citric acid were placed into a mortar and around 14 
drops of ethanol with a Pasteur pipette to make a paste-like consistency. The paste 
was ground and added with a few drops of water before grinding again until dry.  
Li0.1Na0.9H2CIT (Mix 20.9): 0.2 mmol (14.8 mg) Li2CO3, 1.8 mmol (190.8 mg) 
Na2CO3, and 4.0 mmol (768.6mg) citric acid were placed into a mortar and around 14 
drops of ethanol with a Pasteur pipette to make a paste-like consistency. The paste 
was ground and added with a few drops of water before grinding again until dry.  
NaH2CIT (Mix 21): 2.0 mmol (211.9 mg) Na2CO3 and 4.0 mmol (768.5 mg) citric 
acid were placed into a mortar and around 11 drops of ethanol with a Pasteur pipette 
to make a paste-like consistency. The paste was ground and added with a few drops 






Crystallisation from the powder of mixed composition samples was performed by 
slow evaporation. The powder was not soluble in methanol even after heating. DI 
water was added, followed by heating and sonication. After several days, some solid 




Lithium carbonate and sodium carbonate were purchased from Sigma Aldrich while 
orotic acid monohydrate were purchased from Acros Organics. The starting materials 
were used without further purification. The samples were all produced by standard 
mechanochemical procedures whereby the amount of starting materials according to 
the ratio were placed in an agate mortar and pestle and ground with the aid of 
necessary solvent.  
 
Synthesis of Li1-xNaxORO (Mix 3x) where 0 ≥ x ≥ 1 
LiORO (Mix 30): 37.0 mg (0.50 mmol) of Li2CO3 and 174.1 mg (1.00 mmol) of 
orotic acid monohydrate were placed into agate mortar. Using Pasteur pipette, seven 
drops of DI water were added. It was ground for about 10-15 minutes until dry.  
Li0.7Na0.3ORO (Mix 30.3): 25.9 mg (0.35 mmol) of Li2CO3, 15.9 mg (0.15 mmol) 
Na2CO3, and 174.1 mg (1.00 mmol) of orotic acid monohydrate were placed into 
agate mortar. Using Pasteur pipette, seven drops of DI water were added. It was 
ground for about 10-15 minutes until dry.  
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Li0.5Na0.5ORO (Mix 30.5): 18.5 mg (0.25 mmol) of Li2CO3, 26.5 mg (0.25 mmol) 
Na2CO3, and 174.1 mg (1.00 mmol) of orotic acid monohydrate were placed into 
agate mortar. Using Pasteur pipette, seven drops of DI water were added. It was 
ground for about 10-15 minutes until dry.  
Li0.3Na0.7ORO (Mix 30.7): 11.1 mg (0.15 mmol) of Li2CO3, 37.1 mg (0.35 mmol) 
Na2CO3, and 174.1 mg (1.00 mmol) of orotic acid monohydrate were placed into 
agate mortar. Using Pasteur pipette, seven drops of DI water were added. It was 
ground for about 10-15 minutes until dry.  
NaORO (Mix 31): 53.0 mg (0.50 mmol) Na2CO3, and 174.1 mg (1.00 mmol) of orotic 
acid monohydrate were placed into agate mortar. Using Pasteur pipette, seven drops 
of DI water were added. It was ground for about 10-15 minutes until dry.  
Crystallisation 
2 – 3 mg of each sample was dissolved in 1.5 ml DI water and sonicated for 15 mins 
at 60 °C. The solution then was transferred into watch glass covered with parafilm 
with several holes. After several days, some solid precipitated, but they were not 
suitable for single crystals. Attempts were made especially for the sodium orotate 
(NaORO) using different solvents such as ethanol and methanol. In the end, they 
were not successful. 
 
2.2.4. Characterisations 
Powder X-Ray Diffraction (PXRD) 
PXRD was conducted at ambient temperature in PANalytical Empyrean in Bragg-
Brentano geometry using Cu- Kα X-ray radiation (λ = 1.5406 Å) at 40 kV and 10 mA 
power and Pix-Cell detector within 2θ range of 4° – 40°  and in APXRD Proto 
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Manufacturing using Cu-Kα X-ray radiation (λ = 1.5406 Å) at 30kV and 20 mA 
power within 2θ range of 4° – 40°. Silicon zero background disc was used in 
measurement in Empyrean whereas an aluminium sample holder was used in Proto 
Manufacturing. Rietveld refinement is performed using HighScore Plus! Software 
(Degen et al. 2014) from PANalytical. Mercury (Macrae et al. 2008) software is used 
to visualise the reported crystal structures in CSD (Groom et al. 2016) as well as to 
obtain their calculated powder pattern.  
 
Single Crystal X-Ray Diffraction 
Single crystal XRD was performed in Bruker D8 Quest with Cu anode and a Photon 
detector. Data collection and structure solution were performed using Bruker APEX3 
(Bruker 2016) software. Crystal structure refinement was performed with SHELXL 
(G.M. Sheldrick 2015)  in X-Seed (Barbour 2001)  interface. 
 
Thermogravimetric Analysis (TGA) 
TGA was conducted in TA Instruments Q50 with typical sample size 4 - 7 mg in an 
aluminium pan with 20 °C/min rate to 500 °C under sample gas nitrogen flow 
50.0 ml/min. Results were analysed using TA Instruments Universal Analysis 2000 
software. 
 
Dynamic Vapor Sorption (DVS) 
Samples were kept in the oven at 50 °C overnight prior to DVS measurement. DVS 
analysis was performed using DVS Intrinsic (Surface Measurement Systems) with 
water (HPLC grade). The method stage type used was step dm/dt with an equilibrium 
criterion of 0.005 %/min for Li1-xNaxIOR (1x). The dm/dt window was set to 5 
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minutes, with minimum dm/dt stability duration of 10 minutes and maximum dm/dt 
stage time of 360 minutes, and total flow rate was set to 200 sccm. The temperature 
was set to be constant (isotherm) at 25 °C. The relative humidity (RH) was set to 
increase by 10% in sorption cycle and decrease by 10% in desorption cycle. 
 
Particle Size Analysis 
Morphologi G3 from Malvern Panalytical was used to perform particle analysis. 
Using a spatula, the powder sample was placed into the centre of the sample 
dispersion unit. The machine automatically dispersed the powder into the glass plate. 
The magnification used in the measurement was 50x.  
 
2.3. Results and Discussion 
2.3.1. Isoorotate 
Isoorotic acid (2,4-dihydroxypyrimidine-5-carboxylic acid, uracil-5-carboxylic acid) 
is a structural isomer of orotic acid (2,6-dihydroxypyrimidine-4-carboxylic acid, 
uracil-6-carboxylic acid). The use of isoorotate (IOR) as a ligand in a compound 
containing lithium for its potential in lithium therapy was studied (Wagner et al. 
1999), in the monohydrate form (LiIOR·H2O, CSD refcode VEYVUQ). Nichol and 
Clegg (2006) reported crystal structure of sodium isoorotate during a study of 
coordination behaviour of isoorotate complex with alkali metals (NaIOR·H2O, CSD 
refcode ACUFIO).  
In this study, a mechanochemical approach was used to synthesise the compounds. 
Cogrinding the carbonate salts with one equivalent of isoorotic acid with aid of 
deionised water affords white microcrystalline powder. Recrystallisation of the 
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powder from mechanochemical products affords single crystals suitable for X-ray 
diffraction. The unit cells of the crystals are roughly isometrical in the 𝑃21/𝑛 space 
group (Table 2.1).  
LiIOR·H2O (10) crystallises in distorted trigonal bipyramidal geometry, in which the 
lithium coordinates with five oxygen atoms: two from two water molecules, two from 
carboxylate groups in two orotate ions, and one from carbonyl group as shown in 
Figure 2.2. The stacking of two lithium isoorotates are bridged by a water molecule. 
The arrangement creates ladder-like structures. Adjacent ladders are oriented in 
opposite directions. Compared to LiIOR·H2O (10), NaIOR·H2O (11) crystallises in 
octahedral geometry, where the sodium atom coordinates with six oxygen atoms as 
shown in Figure 2.3. Moreover, NaIOR·H2O (11) crystallises in 𝑃21/𝑛, the same 
space group as the lithium counterpart, with similar lattice parameters. These two 
crystals exhibit a behaviour referred to as pseudo-isomorphism (Chao and 
McCullough 1961; d’Agostino et al. 2014). Comparing with calculated patterns of 
VEYVUQ (Wagner et al. 1999) and ACUFIO (Nichol and Clegg 2006) from the 
CSD (Groom et al. 2016), PXRD patterns confirm that the two mechanochemically 
made samples (10 and 11 for Li and Na respectively) are indeed the monohydrate form 
of LiIOR and NaIOR, as shown in Figure 2.4.  
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Table 2.1. Crystallographic data for isoorotate salts  
 LiIOR·H2O (10) LiNaIOR·H2O (10.32) LiNaIOR·H2O (10.60) NaIOR·H2O (11) 
CCDC No* 1884569 1880098 18880097 1884568 
Formula C5 H5 Li N2 O5 
C5 H5 Li 0.68 N2 Na0.32 
O5 
C5 H5 Li0.40 N2 Na0.60 O5 C5 H5 Na N2 O5 
Sp. gr. 𝑃21/𝑛 𝑃21/𝑛 𝑃21/𝑛 𝑃21/𝑛 
a (Å) 3.5184(2) 3.5356(2) 3.543(5) 3.5627(2) 
b (Å) 18.1563(11) 18.1159(12) 18.058(8) 18.0624(7) 
c (Å) 10.3331(6) 10.4169(7) 10.517(12) 10.6069(4) 
β (°) 90.778(4) 91.693(4) 92.35(10) 92.132(3) 
Vol (Å3) 660.03(7) 666.92(7) 672.3(12) 682.09(6) 
Z, Z’ 4, 1 4, 1 4, 1 4, 1 
ρ (g/cm3) 1.812 1.845 1.874 1.910 
Temp (K) 291(2) 291(2) 291(2) 291(2) 
μ (mm-1) 1.409 1.615 1.778 2.028 
R gt (n. refl.) 0.0439 (813) 0.0987 (964) 0.1123 (415) 0.0579 (896) 
*deposition number in the CCDC (Cambridge Crystallographic Data Centre)
42 
 
Table 2.2. Selected distances in the pure compounds 
Distance metal to oxygen LiIOR·H2O (10) NaIOR·H2O (11) 
O8 2.167(6) Å 2.421(3) Å 
O10 1.888(6) Å  2.354(3) Å 
O10_$1 2.140(6) Å 2.411(4) Å 
O10_$2 3.685(6) Å 2.472(3) Å 
O12 2.015(6) Å 2.329(4) Å 









Figure 2.3. Crystal structure of NaIOR·H2O (11) at ambient temperature 
  
Solid solution of LiIOR·H2O and NaIOR·H2O, Li1-xNaxIOR·H2O (1x) where 
0 ≥ x ≥ 1, was attempted mechanochemically. Cogrinding isoorotic acid with one 
equivalent of carbonate salts produced white microcrystalline powder (samples 10.3, 
10.5 and 10.7). PXRD patterns (Figure 2.4) show that these mixed composition samples 
form similar phases to LiIOR·H2O and NaIOR·H2O. The peaks also shift regularly 
with the composition. In contrast, the PXRD pattern of the physical mixtures of 10 
and 11 in 1:1 ratio (PM) show a splitting of the peaks at 12.9° and 27° 2θ validating 
the hypothesis that the coground products are homogeneous phases. This confirms 
that a solid solution can form between LiIOR·H2O and NaIOR·H2O. Single crystal X-
ray diffraction was carried out using single crystals obtained from recrystallisation by 
slow evaporation (Table 2.1). The crystals with mixed composition of Li and Na 
formed solid solution C5H5Li0.68N2Na0.32O5 (LiNaIOR·H2O (10.32)) and 
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C5H5Li0.40N2Na0.60O5 (LiNaIOR·H2O (10.60)). These crystals also crystallise in the 
same space group as the pure compounds. In terms of geometry, they take after the 
geometry of the predominant composition, so C5H5Li0.68N2Na0.32O5 (10.32) has similar 
arrangement to LiIOR·H2O and C5H5Li0.40N2Na0.60O5 (10.60) similar to NaIOR·H2O. 
In this case, the similarity of unit cell parameters and space group of the two crystals 
despite their different geometry arrangements is observed (Table 2.1).  
 
Figure 2.4. PXRD pattern of series Li1-xNaxIOR·H2O (1x). PM is the physical mixture 
LiIOR·H2O NaIOR·H2O 1:1, ACUFIO and VEYVUQ are calculated patterns of CSD refcodes 
for LiIOR·H2O and NaIOR·H2O respectively. 
 
According to Vegard’s law (Vegard 1921), there is a linear relationship between a 
lattice parameter of a solid solution and concentration. Rietveld refinement of the 
PXRD mixed composition samples against the end member was performed to 
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evaluate the unit cell metrics. As expected, the unit cell parameters of solid solution 
Li1-xNaxIOR·H2O vary regularly with the change of compositions (Figure 2.5).  
 
 
Figure 2.5. Unit cell metric in series Li1-xNaxIOR·H2O (1x) 
 
Thermogravimetric analysis reveals that samples 10 to 11 undergo weight loss about 
10% roughly between 130 °C and 210 °C, as in Figure 2.6., which correlates to the 
loss of the coordinate water molecule in the structure. As the content of sodium 
increases, the dehydration occurs at a lower temperature. Lithium has a smaller 
radius; thus, it is a harder acid compared to sodium, therefore affects its chemical and 
structural behaviour. The harder acidity of lithium (chemical hardness of Li+ and Na+ 
are 35.1 eV and 21.1 eV (Parr and Pearson 1983)) and coordination geometry might 
likely cause this behaviour in the series.  
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Table 2.3. Expected vs observed weight loss in TGA 
Internal Ref. 
Code 
Expected weight loss 
Observed weight loss between 
100 °C to 225 °C 
1
0
 10.01% 10.18% 
 1
0.3
 9.75% 9.87% 
 1
0.5
 9.58% 9.46% 
 1
0.7
 9.42% 9.53% 
 1
1
 9.19% 8.34% 
 
 
Figure 2.6. Thermogram of samples Li1-xNaxIOR·H2O (1x) 
 
The humidity stability of the microcrystalline powders was observed by measurement 
of dynamic vapour sorption, as shown in Figure 2.7. Samples with mixed 
composition have higher water uptake than the pure compound 10 and 11 at 80% 
relative humidity, 25 °C. The water uptake of the physical mixture sample (PM) is 
comprised between those of 10 and 11. According to European Pharmacopoeia (2013), 
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at 80% relative humidity and temperature 25 °C, a sample is defined as hygroscopic 
when the mass increase is equal to or greater than 2% and less than 15%. Considering 
that the water uptake for each sample is below 1%, they shall be regarded as not 
hygroscopic. To verify whether the size of the particle affects the sample behaviour, 
particle size analysis was performed. Nevertheless, the particle size distribution is 
rather uniform throughout the series. This eliminates the notion of the effect on 
particle size to its water uptake behaviour. 
 
 




Figure 2.8. Particle size distribution samples Li1-xNaxIOR·H2O (1x) 
 
2.3.2. Dihydrogen Citrate 
The dihydrogen citrate anion (H2CIT) salts (LiH2CIT and NaH2CIT, respectively) are 
isostructural and isomorphous (CSD refcodes LIHCIT and NAHCIT (Glusker et al. 
1965)). LiH2CIT crystals were obtained from evaporating the LiH2CIT solution in the 
oven at 90 °C and NaH2CIT crystals from layering the disodium hydrogen citrate 
solution with propanol at 70 °C on a steam bath (Glusker et al. 1965). Both salts 
crystallise in the monoclinic 𝑃21/𝑎 space group with similar unit cells. The alkali 
metals coordinate with six oxygens from the anions in octahedral manner. Besides the 
anhydrous form, a monohydrate form of LiH2CIT (CSD refcode ZZZREG (Love and 
Patterson 1960)) is also reported without the atomic coordinates in the CSD. 
Similarly, second polymorph of NaH2CIT exists (CSD refcode NAHCIT01 
(Rammohan and Kaduk 2016)) which crystallises in the orthorhombic 𝑃212121. The 
structure was solved from powder pattern of as bought product from a manufacturer 
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(Rammohan and Kaduk 2016). In this second polymorph, the sodium atom is 
surrounded by seven oxygen atoms instead of six.  
A crystal structure for the monohydrate form of LiH2CIT was solved from single 
crystal obtained from slow evaporation crystallisation as mentioned in section 2.2.2. 
The asymmetric unit consists of one molecule of LiH2CIT·H2O. There are eight 
LiH2CIT·H2O molecules in a unit cell. The lithium atom is coordinated with five 
oxygen atoms in total belongs to three different citrate molecules and a water 
molecule in a distorted pyramidal manner. One oxygen atom is from the water 
molecule. Two oxygen atoms are from the central carboxyl group and hydroxyl group 
of one citrate molecule. This formed a five-membered bidentate chelate ring with 
angle of 50.67°. The remaining two oxygen atoms belong to two terminal carboxyl 
groups in two citrate molecules. The repeating units formed a chain-like structures.  
       





Figure 2.10. Coordination of lithium with oxygen atoms in LiH2CIT·H2O 
 
 
Table 2.4. Crystallographic data for LIH2CIT.H2O 
 LiH2CIT·H2O 
Formula C6 H9 Li O8 
Sp. gr. 𝑃𝑏𝑐𝑎 
a (Å) 9.1998(2) 
b (Å) 10.8665(2) 
c (Å) 17.3406(3) 
α (°) 90 
β (°) 90 
γ (°) 90 
Vol (Å3) 1733.53 
Z, Z’ 8, 1 
ρ (g cm-1) 1.656 
Temp (K) Room temp (283-303) 
μ (mm-1) 1.377 




Figure 2.11. PXRD patterns for series Li1-xNaxH2CIT (Mix 2x) as synthesised. LIHCIT, 
NAHCIT, NAHCIT01 are calculated patterns of CSD refcodes for LiH2CIT, NaH2CIT form I, 
and NaH2CIT form II respectively. LiH2CIT·H2O is calculated pattern of the obtained crystal. 
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Figure 2.12. Thermogram of Li1-xNaxH2CIT (Mix 2x) 
 
Manual grinding was used in the attempt of synthesising the samples. Cogrinding 
Li2CO3 or Na2CO3 with citric acid in 1:2 ratio produces microcrystalline powders. 
PXRD pattern of sample Mix 20 matches with the calculated pattern from the solved 
crystal structure of LiH2CIT·H2O (Figure 2.11). TGA profile (Figure 2.12) shows that 
the sample lost about 7% of its weight between 100 – 150 °C, which corresponds to 
one water molecule per formula unit. These facts confirm that mechanochemical 
method affords LiH2CIT·H2O. The sample Mix 20 then was given heat treatment to 
dehydrate the sample by oven incubation overnight at temperature 100 °C. 
Subsequently, the sample was re-ground with pure ethanol prior to PXRD 
measurement. The PXRD pattern shows that it is isostructural to LIHCIT (lithium 
dihydrogen citrate, LiH2CIT), as in Figure 2.13. Meanwhile, the PXRD of 
mechanochemical product Mix 21 results in anhydrous NaH2CIT, as demonstrated by 
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PXRD (Figure 2.11). Its TGA profile shows no significant weight loss up to 190 °C, 
where the decomposition of the anion starts (Figure 2.12). 
Both Li2CO3 and Na2CO3 in various ratio were coground with citric acid. Visual 
inspection of the PXRD patterns (Figure 2.11) suggests that a physical mixture is 
forming between Mix 20 (LiH2CIT·H2O) and Mix 21 (NaH2CIT). Thermogravimetric 
profiles (Figure 2.12) confirm this hypothesis with weight loss that corresponds to 
hydrate presence. To verify whether solid solutions Li1-xNaxH2CIT (where 0 ≥ x ≥ 1), 
can form, all samples were heated to 100 °C and then re-ground in dry ethanol. 
PXRD profiles show new peaks appear in the samples containing sodium. These 
peaks coincide with the second polymorph of NaH2CIT. It has been reported that 
solid solutions can control polymorphism in Co/Zn coordination polymers (Adams et 
al. 2010a). Nevertheless, in this case, this control of polymorphism is not observed as 
the peaks associated with NAHCIT01 still present.  
Rietveld refinement was performed to determine the mixture composition as well as 
to refine the cell parameters for each phase using LIHCIT, NAHCIT, and 
NAHCIT01. From the results (Table 2.5), the phase LiH2CIT found tends to be lower 
in amount than the expected calculation. Nevertheless, the difference is small (4 to 
10%). Because the value is close to the limit of detection, for this technique the 






Figure 2.13. PXRD patterns for series Li1-xNaxH2CIT (Mix 2x) after heat treatment & 
reground with pure ethanol. LIHCIT, NAHCIT, NAHCIT01 are calculated patterns of CSD 
refcodes for LiH2CIT, NaH2CIT form I, and NaH2CIT form II respectively. 
 
Table 2.5. Rietveld refinement of sample Mix 2x  
 Expected (wt%) Found (wt%) 
Li Na LIHCIT NAHCIT NAHCIT01 
Mix 20.1 89.28 10.72 86.7(4) 4.8(9) 8.4(3) 
Mix 20.3 64.34 31.66 64.7(3) - 35.3(6) 
Mix 20.5 48.05 51.95 43.7(7) 44.0(8) 12.2(5) 
Mix 20.7 28.39 71.61 19(1) 62.3(2) 18.6(9) 
Mix 20.9 9.32 90.68 - 52.8(3) 47.2(8) 
 
It is worth noting that in sample Mix 21 a conversion from the initial form I 
(NAHCIT) to form II (NAHCIT01) occurs with time. Heating the sample to 100 °C 
overnight can hinder, but not completely stop such transformation (Figure 2.15). 
Visual inspection of the PXRD pattern (Figure 2.14) suggests that the conversion 
starts around day 3 in the sample without heat treatment. By day 8, the pattern is 
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completely different from NAHCIT (Figure 2.14). It seems like the second 
polymorph (NAHCIT01) is the stable form of NaH2CIT.  
 
Figure 2.14. PXRD patterns of sample Mix 21 with no heat treatment. NAHCIT and 





Figure 2.15. PXRD patterns of sample Mix 21 with heat treatment between measurements in 
day 0 and day 1. NAHCIT and NAHCIT01 are calculated patterns of CSD refcodes for 




The reported Li orotate (ORO) (CSD refcode SIMZOD (Bach et al. 1990)), is a 
monohydrate form and crystallise in space group 𝑃1. The compound forms staggered 
planar sheets. The lithium atom coordinates with four oxygen atoms in a tetrahedral 
geometry. The distances of Li – O are 1.880(4) Å, 1.892(4) Å, 1.950(3) Å, and 




Figure 2.16. Structure arrangement of SIMZOD01 (top) and stacking (bottom) 
 
The PXRD pattern of mechanochemically made Mix 30 reveals that it is isostructural 
to the calculated pattern of SIMZOD, as shown in Figure 2.17. TGA profile in     
Figure 2.18 also showed that Mix 30 undergo weight loss after about 200 °C, which 
equal to about one molecule of water, indicating a monohydrate. The water molecule 
that coordinates with the metal ion is a typical representation of (metal) ion 
coordinated hydrate (Pöppler et al. 2016). The interaction of metal – water is strong. 
Therefore it losses water at higher temperature. These confirm that Mix 30 is indeed a 
LiORO·H2O compound. The other mechanochemically made pure compound Mix 31 
was measured in PXRD. As there is no crystal structure of sodium orotate (NaORO) 
compound, no calculated pattern can be used to compare with the PXRD pattern of 
Mix 31. Slow evaporation crystallisation from powder was attempted as well as from 
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the solution method. However, the quality of the resulting solids is not adequate for 
single crystal XRD. Thus the structure remains unsolved. TGA for Mix 31 reveals 
that it does not undergo weight loss as Mix 30; it is stable until about 300 °C and 
starts to decompose. This fact indicates that the Mix 31 is an anhydrate, not a 
monohydrate like Mix 30.  
 
Figure 2.17. PXRD patterns of samples Li1-xNaxORO (Mix 3x). SIMZOD is calculated pattern 
of CSD refcode for LiORO·H2O. 
 
A solid solution of LiORO and NaORO, Li1-xNaxORO (Mix 3x) where 0 ≥ x ≥ 1, is 
attempted by cogrinding orotic acid monohydrate with Li2CO3 and Na2CO3 in various 
ratio. The samples with mixed ratio of Li and Na were also measured in PXRD and 
TGA. The PXRD patterns of these samples indicate that those are physical mixture 
rather than solid solution, as indicated by the appearance of the peak from Mix 30 and 
Mix 31. End members Mix 30 and Mix 31 were physically mixed in 1:1 ratio (labelled 
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PM in Figure 2.17), and its PXRD pattern looks like that PXRD of Mix 30.5. This 
confirms that the mixed composition products are indeed physical mixtures. TGA 
profiles show that the mixed ratio samples tend to lose weight according to the ratio 
(Table 2.6). This behaviour is expected from the physical mixture.  
 
Figure 2.18. Thermogram of samples Li1-xNaxORO (Mix 3x) 
 
Table 2.6. Weight loss of samples during TGA measurement 
Internal 
Ref. Code 
Weight loss between 100 °C and 250 °C Calculated water molecule 
3
0
 10.20% 1.03 
 3
0.3
 7.09% 0.71 
 3
0.5
 5.09% 0.51 
 3
0.7
 3.06% 0.31 
 3
1
 0.48% 0.05 
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From the PXRD patterns and TGA profiles of Mix 30 and Mix 31, it can be concluded 
that they are not isostructural. The fact that the two end members have different forms 
(monohydrate and anhydrous) also adds the obstacle in the solid solution formation. 
Li atoms in the lithium orotate monohydrate coordinates with four oxygen atoms, 
three from orotate ions (two of carbonyl and one of carboxyl) and one from a water 
molecule. Na atom might coordinate in a different manner compared to Li atom in the 
orotate compound.  
 
2.4. Conclusion 
Three anions (isoorotate (IOR), dihydrogen citrate (H2CIT), and orotate (ORO)) were 
used in attempts to form solid solutions with varying the ratio of lithium and sodium. 
Manual grinding and solution synthesis afford samples of homogeneous solid 
solution of Li1-xNaxIOR·H2O (1x) despite the different coordination of parent 
structures, as shown by single crystal XRD. In the compounds with the dihydrogen 
citrate ion (C6H7O7-), cogrinding produces LiH2CIT·H2O which needs to be 
dehydrated to form LiH2CIT. Nevertheless, it affords NaH2CIT straightforwardly. 
Interestingly, NaH2CIT transforms where the form I converts into the form II over 
time. LiH2CIT and the form I of NaH2CIT are isomorphous pair. Straightforward 
synthesis of Li1-xNaxH2CIT through cogrinding failed as PXRD patterns suggest that 
the mixed composition samples are physical mixtures of LiH2CIT·H2O and NaH2CIT 
in various ratio. This is corroborated by TGA results where they exhibit intermediate 
behaviour of the two end members. Heat treatment of Li1-xNaxH2CIT manages to 
produce the anhydrous forms. Control of polymorphism is not observed, as new 
peaks associated to the form II of NaH2CIT appear. Cogrinding Li2CO3 with orotic 
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acid monohydrate in 1:2 ratio produces LiORO·H2O as confirmed by PXRD and 
TGA. Substituting Li2CO3 with Na2CO3 results in an anhydrous compound, however, 
there is no reported structure for this. Crystallisation failed to yield good quality 
crystals for structure determination. Attempt to produce Li1-xNaxORO yields physical 
mixtures of the two end members instead of solid solution.  
In conclusion, solid solutions of lithium and sodium are possible with appropriate 
anion, in this case isoorotate, despite the large size (in terms of van der Waals radius, 
Na is about 25% larger than Li) and chemical properties difference. A virtually 
complete solubility is possible in the isoorotate system whose parent compounds have 
different geometric coordination. The water molecule is speculated to enable its high 
solubility, since it can attach easily to the metal atom without disrupting the crystal 
packing. This behaviour is not observed in the orotate system, where monohydrate 
and anhydrate forms are produced which may impede the solid solution formation. 
No solid-state solubility is present in the dihydrogen citrate system despite the 
isomorphous and isostructural nature of the parent compounds. However, these 
observations disagree with the Hume-Rothery rules of solid solubility and 
Kitaigorodsky’s suggestion on isostructurality in solid solutions (Kitaigorodsky 
1984). The sizes of the atoms differ rather largely, yet complete solid solubility is 
possible in the isoorotate system. Ultimately, this study presents an example of a solid 
solution of lithium and sodium molecular salts with sufficient thermal and humidity 
stability capable for utilisation as drug therapy. Such mixed salt could assist in 
maintaining the sodium concentration in the serum and lithium metabolism in bipolar 


















Chapter 3  
Lithium Coordination Polymers2  
 
3.1. Introduction  
Coordination polymers are, perhaps, an overlooked class of materials in the 
pharmaceutical research in comparison to other crystalline forms, such as neutral 
molecules, salts, hydrates, solvates, and cocrystals. A coordination polymer has 
repeating coordination entities extend in one, two, or three-dimensions (Batten et al. 
2013). Coordination polymers have potential in several applications such as gas 
storage, gas separation, optical, and many others. In relation to medicines and 
pharmaceuticals, they have been studied regarding their potential for drug delivery 
(Imaz et al. 2010; Ma and Moulton 2011), including the hybrid organic and inorganic 
porous materials for drug delivery (Horcajada et al. 2006; McKinlay et al. 2010). 
However, coordination polymers containing active pharmaceutical ingredients (API) 
are relatively rare. Braga et al. (2008) reported coordination compounds of an API 
called gabapentin with zinc and copper. The use of these materials might affect the 
properties of APIs such as solubility and bioavailability. Another example of 
coordination polymer containing API is a 1-D polymer of nalidixic acid with zinc, 
                                                            
2 The work in this chapter appears in  
Lestari, M., Lusi, M., O'Leary, A., O'Nolan, D. and Zaworotko, M.J. (2018) 
'Hygroscopicity of lithium coordination polymers and their solid solutions', 




which reported to be more soluble than the nalidixic acid itself (André et al. 2018). 
2-D coordination polymers containing lithium with organic acids and amino acid 
show better blood-brain barrier permeability than lithium carbonate (Zaworotko et al. 
2017) thus, they have potentials as psychiatric medication. Moreover, Zaworotko et 
al. (2017) suggested that lithium coordination polymers may be less hygroscopic than 
salts. 
In this work, solid solutions of lithium coordination polymers are attempted. The 
hygroscopicity of the products are to be investigated since it is detrimental in the 
pharmaceutical compounds. The hygroscopicity of a material can be represented by 
its water uptake. In one case, known {Li[MBNZ]Pro}n and {Li[BNZ]Pro}n  
(Zaworotko et al. 2017)  are combined to produce {Li[MBNZ]x[BNZ]1-xPro} n where 
MBNZ = 2-methoxybenzoate, BNZ = benzoate, Pro = L-Proline, 0 ≤ x ≤ 1. In a 
second instance, {Li2[SUC]}n and {Li2[MAL]}n are combined to obtain 
{Li2[SUC]x[MAL]1-x}n  (where SUC = succinate, MAL = malate, 0 ≤ x ≤ 1). The pure 
compounds are reported in different space groups: {Li2[SUC]}n in 𝑅3̅ and 
{Li2[MAL]}n in 𝑅3 and are known to form a ternary solid solution with {Li2(MET)}n 
(MET = methysuccinate) (Yeung et al. 2013)  
 
3.2. Experimental 
3.2.1. {Li[MBNZ]x[BNZ]1-xPro}n Solid Solutions 
Starting materials 2-methoxybenzoic acid, benzoic acid, lithium hydroxide, and L-
proline were purchased from Sigma Aldrich and used without further purification. 
The synthesis was carried out by mechanochemical method.  
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Figure 3.1. 2-methoxybenzoic acid, benzoic acid, and L-proline 
{[(PRO)Li(MBNZ)]}n (40): 12.0 mg LiOH (0.501 mmol), 76.1 mg 2 methoxybenzoic 
acid (0.500 mmol), 57.6 mg L-proline (0.500 mmol) were placed in a mortar with two 
drops of deionised water (using Pasteur pipette) and were ground for about 10 – 15 
minutes. 
{[(PRO)Li(MBNZ)0.75(BNZ)0.25]}n (40.25): 12.0 mg LiOH (0.501 mmol), 57.2 mg 
2-methoxybenzoic acid (0.376 mmol), 15.5 mg benzoic acid (0.127 mmol), 57.6 mg 
L-proline (0.500 mmol) were placed in a mortar with two drops of deionised water 
(using Pasteur pipette) and were ground for about 10 – 15 minutes. 
{[(PRO)Li(MBNZ)0.50(BNZ)0.50]}n (40.50): 12.0 mg LiOH (0.501 mmol), 38.1 mg 
2-methoxybenzoic acid (0.250 mmol), 30.6 mg benzoic acid (0.251 mmol), 57.6 mg 
L-proline (0.500 mmol) were placed in a mortar with two drops of deionised water 
(using Pasteur pipette) and were ground for about 10 – 15 minutes. 
{[(PRO)Li(MBNZ)0.25(BNZ)0.75]}n (40.75): 12.0 mg LiOH (0.501 mmol), 19.0 mg 
2-methoxybenzoic acid (0.125 mmol), 45.9 mg benzoic acid (0.376 mmol), 57.6 mg 
L-proline (0.500 mmol) were placed in a mortar with two drops of deionised water 
(using Pasteur pipette) and were ground for about 10 – 15 minutes. 
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{[(PRO)Li(BNZ)]Sn (41): 12.0 mg LiOH (0.501 mmol), 61.1 mg benzoic acid 
(0.500 mmol), 57.6 mg L-proline (0.500 mmol) were placed in a mortar with two 
drops of deionised water (using Pasteur pipette) and were ground for about 10 – 15 
minutes. 
Recrystallisation 
The mechanochemical product was dissolved in a minimum amount of water, 
sonicated at 40 °C for 15 minutes and recrystallised by slow solvent evaporation. 
Colourless single crystals appeared within a week. 
 
3.2.2. {Li2[SUC]x[MAL]1-x}n Solid Solutions  
Starting materials lithium carbonate, succinic acid, and L-malic acid were purchased 
from Sigma Aldrich and used without further purification. The synthesis was carried 
out via mechanochemistry method where the materials were placed in agate mortar 
and added with small amount of solvent prior to grinding.  
             
 
Figure 3.2. Succinic acid and L-malic acid 
  
{[Li2(SUC)]}n (50): 73.9 mg Li2CO3 (1.00 mmol) and 118.1 mg succinic acid 
(1.00 mmol) were placed in a mortar with 40 μL of deionised water and were ground 
until forming white paste consistency. 30 μL of deionised water was added into the 
mortar and were ground for about 10 - 15 minutes until the powder dried. 
67 
{[Li2(SUC)0.8(MAL)0.2]}n (50.2): 73.9 mg Li2CO3 (1.00 mmol), 26.8 mg L-(-) malic 
acid (0.20 mmol), and 94.5 mg succinic acid (0.80 mmol) were placed in a mortar 
with 40 μL of deionised water and were ground until forming white paste 
consistency. 30 μL of deionised water was added into the mortar and were ground for 
about 10 - 15 minutes until the powder dried. 
{[Li2(SUC)0.6(MAL)0.4]}n (50.4): 73.9 mg Li2CO3 (1.00 mmol), 53.6 mg L-(-) malic 
acid (0.40 mmol), and 70.9 mg succinic acid (0.60 mmol) were placed in a mortar 
with 40 μL of deionized water and were ground until forming white paste 
consistency. 30 μL of deionised water was added into the mortar and were ground for 
about 10 - 15 minutes until the powder dried. 
{[Li2(SUC)0.5(MAL)0.5]}n (50.5): 73.9 mg Li2CO3 (1.00 mmol), 67.1 mg L-(-) malic 
acid (0.50 mmol), and 59.1 mg succinic acid (0.50 mmol) were placed in a mortar 
with 40 μL of deionised water and were ground until forming white paste 
consistency. 30 μL of deionised water was added into the mortar and were ground for 
about 10 - 15 minutes until the powder dried. 
{[Li2(SUC)0.4(MAL)0.6]}n (50.6): 73.9 mg Li2CO3 (1.00 mmol), 80.5 mg L-(-) malic 
acid (0.60 mmol), and 47.2 mg succinic acid (0.40 mmol) were placed in a mortar 
with 40 μL of deionised water and were ground until forming white paste 
consistency. 30 μL of deionised water was added into the mortar and were ground for 
about 10 - 15 minutes until the powder dried. 
{[Li2(SUC)0.2(MAL)0.8]n (50.8): 73.9 mg Li2CO3 (1.00 mmol), 107.3 mg L-(-) malic 
acid (0.80 mmol), and 23.6 mg succinic acid (0.20 mmol) were placed in a mortar 
with 40 μL of deionised water and were ground until forming white paste 
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consistency. 30 μL of deionised water was added into the mortar and were ground for 
about 10 - 15 minutes until the powder dried. 
{[Li2(MAL)]}n (51): 73.9 mg Li2CO3 (1.00 mmol) and 134.1 mg L-(-) malic acid 
(1.00 mmol) were placed in a mortar with 40 μL of deionised water and were ground 
until forming white paste consistency. 30 μL of deionised water was added into the 
mortar and were ground for about 10 - 15 minutes until the powder dried. 
 
3.2.3. Characterisations 
Powder X-Ray Diffraction (PXRD) 
Powder X-ray diffraction (PXRD) measurements for the mechanochemically made 
samples were performed on the PANalytical Empyrean with Bragg-Brentano 
geometry at ambient temperature equipped with a sealed tube X-ray generator with a 
Cu anode (Kα1,2 = 1.540598), and Pix-Cell detector on zero background discs. 
Variable temperature PXRD (VT-PXRD) measurement for sample (41) was measured 
in X’Pert Pro with a Cu anode (Kα1 = 1.540598) with Anton Paar TTK-450 stage. 
Measurement was performed at non-ambient temperature 25 °C, 100 °C, 150 °C and 
25 °C. 
 
Single Crystal X-Ray Diffraction and Structure Determination 
Single crystal data were collected at low temperature (and ambient temperature for 
the pure component crystals 40 and 41, as displayed in Table 3.1) using Bruker D8 
Quest with sealed tube Mo anode and a Photon detector. The data were integrated and 
corrected for absorption with the Bruker APEX Suite of programs. The structure 
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solution was obtained by direct methods and refined against all F2 with the SHELX 
(G.M. Sheldrick 2015) software interfaced through X-Seed (Barbour 2001). Non-
hydrogen atoms were refined anisotropically and hydrogen atoms were placed in 
calculated positions refined using idealised geometries (riding model) and assigned 
fixed isotropic displacement parameters. 
 
Thermogravimetric Analysis (TGA) 
Thermogravimetric analysis (TGA) was performed in Perkin Elmer TGA 4000 with a 
typical sample size of 4.8 – 5.6 mg under the ramp rate of 20.00 °C/min from 35 °C 
to 400 °C and nitrogen gas flow of 20 ml/min.  
 
Dynamic Vapor Sorption (DVS) 
Dynamic vapour sorption (DVS) measurements were performed on DVS Intrinsic 
(Surface Measurement System). The method stage type used was step dm/dt with an 
equilibrium criterion of 0.002 %/min. The dm/dt window was set to 5 minutes, with 
minimum dm/dt stability duration of 10 minutes and maximum dm/dt stage time of 
360 minutes, and total flow rate was set to 200 sccm. The temperature was set to be 
constant (isotherm) at 25 °C. The relative humidity (RH) was set to increase by 10% 
from 0% to 90% and back to 0%. 
 
3.3. Results and Discussion 
3.3.1. {Li[MBNZ]x[BNZ]1-xPro}n Solid Solutions 
Lithium, 2-methoxybenzoate, and L-Proline in 1:1:1 ratio form a 2-D coordination 
polymer {Li[MBNZ]Pro}n (40)  with square-grid (sql) structure, as illustrated in 
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Figure 3.3. It crystallises in monoclinic 𝑃21 space group. The lithium atom serves as 
a metal node that coordinates in a tetrahedral manner with four oxygen atoms from 
two 2-methoxybenzoate and two proline ligands. The carboxylate functional group of 
2-methoxybenzoate anion bridges between the metal nodes along a axis. Meanwhile, 
on the bc crystallographic plane, the metal nodes are connected by the proline 
zwitterion. This arrangement results in the square-grid structure. The stacking of the 
polymeric chain is along the c axis. The ligands 2-methoxybenzoate and proline are 
in alternating arrangement along b axis. On the contrary, along a axis the ligands are 
facing the same direction.  
Benzoate forms {Li[BNZ]Pro}n (41) (Figure 3.4), which retains the 2-D square-grid 
structure but crystallises in orthorhombic 𝑃21212 (higher symmetry than 
{Li[MBNZ]Pro}n (40)). Here, the lithium atom also coordinates with four oxygen 
atoms in the same manner. The ligands along a axis are always facing the same 
direction whereas along b axis the directions of the ligands are inverted alternatingly. 
















Figure 3.5. Square-grid structure of coordination polymer {Li[MBNZ]Pro}n (40) (left) and 
{Li[BNZ]Pro}n (41) (right) at ambient temperature. 
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Table 3.1. Crystallographic data of lithium coordination polymers crystals 
 40 40 40.07 40.90 41 41 
CCDC No* 1845829 1845832 1845831 1845834 1845833 1845830 
Formula C13 H16 Li N O5 C13 H16 Li N O5 C12.93 H15.87 Li N O4.93 C12.09 H14.18 Li N O4.09 C12 H14 Li N O4 C12 H14 Li N O4 
Mr (g mol-1) 273.21 273.21 271.20 245.88 243.18 243.18 
System Monoclinic Monoclinic Monoclinic Orthorhombic Orthorhombic Orthorhombic 
Sp. gr. 𝑃21 𝑃21 𝑃21 𝑃21212 𝑃21212 𝑃21212 
a (Å) 5.4363(7) 5.4170(3) 5.4205(7) 10.0666(9) 10.0679(5) 10.1119(18) 
b (Å) 10.3418(13) 10.3590(6) 10.3464(13) 10.5869(8) 10.5702(6) 10.5584(19) 
c (Å) 11.8349(17) 11.4916(6) 11.5006(15) 11.7836(8) 11.7537(7) 11.746(2) 
β (°) 99.739(5) 99.5520(10) 99.500(4) 90 90 90 
Vol (Å3) 655.78(15) 635.91(6) 636.14(14) 1255.83(17) 1250.83(12) 1254.1(4) 
Z, Z’ 2, 1 2, 1 2, 1 4, 1 4, 1 4, 1 
ρ (g cm-3) 1.384 1.427 1.416 1.301 1.29 1.288 
Temp (K) 293 100 100 100 100 293 
μ (mm-1) 0.105 0.108 0.107 0.096 0.095 0.095 
R gt (n. refl.) 0.0422 (1225) 0.0192 (1780) 0.0400 (1547) 0.0483 (1720) 0.0450 (3066) 0.0664 (2669) 
*deposition number in the CCDC (Cambridge Crystallographic Data Centre)  
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Figure 3.6. PXRD patterns of series {Li[MBNZ]x[BNZ]1-xPro}n (4x), with calculated pattern 
from single crystal (41) and (40) as well as starting materials. BNZ, MBNZ, PRO, LiOH are 
starting materials, benzoic acid, 2-methoxybenzoic acid, L-proline, and lithium hydroxide 
respectively.  
 
The synthesis of {Li[MBNZ]x[BNZ]1-xPro}n solid solution was attempted despite of 
the non-isostructural nature of the parents {Li[MBNZ]Pro}n (40)  and {Li[BNZ]Pro}n 
(41). Colourless crystals suitable for X-ray diffraction grow from slow evaporation of 
solution with various ratio of MBNZ and BNZ. Multiple single crystals were 
collected and characterised by single crystal XRD. Structure refinement confirmed 
the co-presence of BNZ and MBNZ ligands in both monoclinic and orthorhombic 
phases (Table 3.1). The single crystal data suggest that the possible ligand 
substitution for each phase is maximum 10% and maintains the same structure as the 
dominant end member. Mechanochemical approach to obtain the solid solution was 
performed by grinding LiOH, L-proline, and 2-methoxybenzoic acid / benzoic acid 
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according to the ratio. In this case, the existence of a homogeneous solid solution 
cannot be confirmed by their PXRD patterns. The PXRD patterns of the mixed 
composition series display a continuous peak shifting.  
 
Figure 3.7. Thermogram of series {Li[MBNZ]x[BNZ]1-xPro}n (4x) 
 
Thermogravimetric profiles of the samples reveal that the coordination polymers are 
generally stable at high temperature before start to decompose after 200 °C       
(Figure 3.7). The onset temperature of each sample varies depending on the 
composition. There is a slight deviation occurs on the sample (41) of the 
mechanochemical product, where it lost about 4% of its weight at around 150 °C. 
Variable temperature PXRD was performed for sample (41), where it was measured at 
25 °C, 100 °C, 150 °C, and back to 25 °C (Figure 3.8). The profile of the initial scan 
at 25 °C shows peaks that are not visible at the profile of the last scan at 25 °C. The 
disappearing peaks are likely due to a small amount of unreacted benzoic acid that is 
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undetected in ambient temperature PXRD (melting point of benzoic acid is about 
122 °C). Hence, the peaks are not observable in the scan profile at 150°C.  
 
 
Figure 3.8. Variable temperature PXRD patterns of the sample (41) at 25 °C (bottom, blue), 
100 °C (green), 150 °C (orange), and back to 25 °C (top, red) 
 
The water uptake behaviour of the lithium coordination polymers is measured by 
dynamic vapour sorption. In the sorption measurement, the sample from 
mechanochemical method was exposed to 10% increment of the relative humidity 
from 0% to 90% and back to 0% isothermally at 25 °C. At 80% relative humidity, 
sample (41) has the least water uptake in the series. Mixed composition samples are 
observed to have higher water uptake than the parent compounds, which can be 
classified as hygroscopic according to the European Pharmacopeia (2013). This 
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behaviour hints that the mechanochemical synthesis yields a series of solid solutions. 
Solid solution series can have properties that are completely different from the end 
members. Theoretically, water uptake by a mixture of the pure compounds will be 
linearly varied with the mixture ratio. As expected, the water uptake profile of the 
physical mixture sample (PM) of (41) and (40) in 1:1 ratio lies roughly between the 
two pure compounds. The hygroscopicity behaviour of the mixed composition is 
speculated to be a consequence of increasing lattice energy. Replacing a component 
in the crystal structure can increase lattice energy rapidly, which limit the solid-state 
solubility, as observed in this series (4x). 
 
Figure 3.9. Sorption cycle of DVS measurement for series {Li[MBNZ]x[BNZ]1-xPro}n (4x). 
PM is the physical mixture 1:1 of   (41) and (40). 
 
It is also observed that, during the DVS run, most samples undergo changes. A 
sample can exhibit deliquescent behaviour, where it absorbs sufficient water until it 
forms a liquid. This is observed except in the sample (41), which is not hygroscopic. 
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These samples are recrystallised on the DVS sample pan, and the most obvious 











     
Figure 3.10. Observation of samples after DVS run 
 
 
3.3.2. {Li2[SUC]x[MAL]1-x}n Solid Solutions  
A complete ternary solid solution {Li2[SUC]x[MAL]y[MET]z}n (SUC = succinate, 
MAL = malate, MET = methylsuccinate, where x + y + z = 1) can be obtained by 
grinding the pure end members (Yeung et al. 2013). Based on the series as mentioned 
earlier, solid solution {Li2[SUC]x[MAL]1-x}n  (5x) where 0 ≤ x ≤ 1 is synthesised. As 
hygroscopicity is generally undesirable in drug products, it is valuable to address such 
behaviour in different systems of solid solutions with lithium coordination polymers. 
This solid solution series serves as a comparison to investigate the generality of the 
water uptake behaviour. As previously mentioned, the parent structures {Li2[SUC]}n 
crystallises in 𝑅3̅ (CSD refcode LISUCC01 (Yeung et al. 2013)) and {Li2[MAL]}n in 
𝑅3 (CSD refcode REXBED (Yeung et al. 2013)). Thus, they are isostructural pair. 
Grinding Li2CO3 with malic acid and succinic acid in various ratios with the aid of 
deionised water affords the mixed composition samples, as shown in the PXRD 
patterns, where those of the mixed composition samples are isostructural to those of 
the parent compounds.  
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The profile DVS measurement shows that at 80% relative humidity and 25 °C, the 
water uptake behaviour increases more regularly with composition. In this series, the 
sample (50) has the least water uptake, whose value is below the hygroscopic 
category. Moreover, the mixed composition samples absorbed water in a rather 
continuous manner from (50) to (51) with deviation in the sample (50.8), which 
absorbed most water than the rest of the samples. Contrary to (4x) that has partial 
solubility, the system with complete solubility nature as this series (5x) has a smaller 
increase in lattice energy (smaller enthalpy) upon substitution. Hence, the water 
uptake behaviour is more regular as the composition changes.  
 
 
Figure 3.11. PXRD patterns for series {Li2[SUC]x[MAL]1-x}n (5x) with calculated pattern 
REXBED (top) and LISUCC01 (bottom) 
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Figure 3.12. Sorption cycle of DVS measurement for series {Li2[SUC]x[MAL]1-x}n (5x) 
 
3.4. Conclusion  
Solid solutions comprised of lithium coordination polymers are investigated. A non-
isostructural pair of two coordination polymers serve as the parent compounds: 
{Li[MBNZ]Pro}n and {Li[BNZ]Pro}n. They contain lithium, an API for bipolar 
disorder. Structure determination from the single crystals obtained from 
crystallisation reveals that a solid solution is feasible in such system despite the non-
isostructural characteristics, with limited ligand substitution. In fact, the solid solution 
can be isomorphous to either of the parent compounds, whose crystal systems are 
monoclinic and orthorhombic, respectively, depending on the relative amount of 
ligands.  PXRD of the samples are unable to confirm the homogeneity of the 
mechanochemical product. Nevertheless, the patterns show peak shifting typical of 
most solid solutions. Most samples show thermal stability until about 200 °C. DVS 
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reveals that water uptake is higher in the mixed composition samples than in the 
parent compounds. As expected, the water uptake for the physical mixture lies in 
between the parent compounds. Thus, all of the samples with mixed composition can 
be considered as hygroscopic (European Pharmacopoeia 2013).  
In contrast with the first series, which is composed of a non-isostructural pair, the 
second series is of an isostructural pair. In this second series, the water uptake 
behaviour is rather linear. We speculate that the lattice energy affects the 
hygroscopicity behaviour in these series. If more similar compounds are mixed, they 
will have smaller enthalpy variation (Lusi 2017), thus affecting the solid-state 
solubility. In the series with limited solid solubility, the mixed composition crystals 
are less stable since they have bigger lattice energy (higher enthalpy) than the parent 
compounds. Hence they need less energy for hydration. Nevertheless, from a 
pharmaceutical perspective, this study demonstrates that this class of materials can 












Chapter 4  
Cortisone and Hydrocortisone 
 
This chapter is a part of collaboration with Mr Kieran Lyons for crystallisation, Dr 
Vivek Verma for supercritical CO2 synthesis and dissolution test of solid solutions, 




Cortisone (17,21-dihydroxypregn-4-ene-3,11,20-trione) and cortisol 
(11β,17,21-trihydroxypregn-4-ene-3,20-dione) are hormones produced in the adrenal 
cortex. In human body, 11β-hydroxysteroid dehydrogenase is crucial in the regulation 
of these glucocorticosteroid hormones. The enzyme acts as the catalyst in the 
interconversion of cortisol and cortisone (Lakshmi and Monder 1985; Edwards et al. 
1988). Both hormones are derived from cholesterol. Thus generally steroids tend to 
be poorly soluble in water. Cortisol is the principal glucocorticosteroid in human and 
has many functions, including stress response and blood glucose controls. Cortisol is 
known as hydrocortisone when used as medication. Hydrocortisone is used to treat 
allergies and minor skin irritations due to its anti-inflammatory activity (Michelle 
Garay et al. 2007) and widely available for topical application. World Health 
Organization lists hydrocortisone as essential medicines (World Health Organization 
2017). Cortisone is a precursor of cortisol. This conversion occurs in the liver. Since 
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cortisone has to be converted in vivo, it is not as effective as hydrocortisone for 
treating dermatologic diseases when used as a topical application (Becker 2001).  
In terms of crystal structure, hydrocortisone has three reported polymorphs: form I in 
orthorhombic P212121 (ZZZPNG01), form II in monoclinic P21 (ZZZPNG02), and 
form III in orthorhombic P212121 (ZZZPNG03) (Suitchmezian et al. 2008). Cortisone 
crystallises in the orthorhombic P212121 space group (DHPRTO (Declercq et al. 
1972)).  
  
Figure 4.1. Cortisone and hydrocortisone 
 
Multicomponent forms of steroids class have been studied, for example, in the pairs 
arenobufagin and gamabufotalin (Argay et al. 1987), and in cinobufagin and 
cinobufotalin (Kalman et al. 1988). Adducts with ratio 1:1 of 
arenobufagin  – gamabufotalin and 1:1 cinobufagin – cinobufotalin yield crystals with 
the same space group as their parent structures and maintain to have the 
approximately similar lattice parameters (Kalman et al. 1992).  A disordered crystal 
form can arise too, such as in the crystal of mixed cortisol and iodocortisol 
(Castellano et al. 1980). The two compounds differ in the atom C21, where OH group 
is present in cortisol and iodine atom replaces it in the other compound. Iodocortisol 
in that crystal has occupation number of 0.18. The bond length of C – I is shorter than 




Figure 4.2. Gamabufotalin, arenobufagin, cinobufagin, and cinobufotalin 
 
 
Here we studied the possibility of producing solid solutions of cortisone and 
hydrocortisone, which would represent a prodrug-drug system. From the 
crystallographic point of view, this system is interesting because size and shape 
similarity is deemed crucial in forming solid solutions. In contrast, the steroids under 
consideration have different crystal packing and are not isostructural. Although 
hydrocortisone form I and cortisone are crystallised in the orthorhombic P212121 
space group, their unit cell parameters are not similar. In terms of the structure, in 
position C11 cortisone has a carbonyl group while hydrocortisone has a hydroxyl 
group. The solid solution would require an equivalent environment in the carbonyl 
and the hydroxyl groups, which intervene in diverse H-bond interactions. 
86 
Besides the slow evaporation to produce single crystals, we used the established 
synthetic route of mechanochemistry by manual grinding. An alternative method of 
synthesis was attempted with the aid of supercritical CO2. The method GAS (Gas 
Antisolvent) uses CO2 in supercritical condition as antisolvent.  The use of 
supercritical fluids has been studied in many applications, including for 
pharmaceuticals. A method called rapid expansion of supercritical fluid solutions 
(RESS) with CO2 has reported to be applied in the anthracene and phenanthrene 
system (Liu and Nagahama 1997).  Using carbon dioxide as supercritical fluid is the 
most common since it is non-carcinogenic, non-toxic, non-mutagenic, non-
flammable, and thermodynamically stable (Knez et al. 2014). Supercritical CO2 can 
be utilised in three different roles: 1) as a solvent, 2) as an antisolvent, and 3) as 
atomization enhancer (Long et al. 2019).  
 
4.2. Experimental 
4.2.1. Slow Evaporation and Mechanochemical Method  
Cortisone (C) and hydrocortisone (HC) from Sigma Aldrich were used in the 
experiment without further purification.  
For the slow evaporation crystallisation, a small amount of the cortisone, 
hydrocortisone, and cortisone and hydrocortisone in mixed ratio was dissolved in 
ethanol and sonicated for 5 minutes. The solution of the pure compounds and the 
mixed ratios were placed in vials and covered by parafilm with few holes to facilitate 
slow evaporation. After several days, single crystals appeared. Suitable crystals 61, 62, 
and 63 were measured with SCXRD.  
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The mechanochemical method here refers to solvent assisted grinding using agate 
mortar and pestle.  
Cortisone:Hydrocortisone 2:1 (mc C:HC 2:1) 
72.0 mg (0.20 mmol) of cortisone and 36.3 mg (0.10 mmol) of hydrocortisone were 
placed in the mortar and ground manually. 4-5 drops of ethanol were added using 
Pasteur pipette before starting to grind the mixture for about 5-10 minutes.   
Cortisone:Hydrocortisone 1:1 (mc C:HC 1:1) 
54.1 mg (0.15 mmol) of cortisone and 54.4 mg (0.15 mmol) of hydrocortisone were 
placed in the mortar and ground manually. 4-5 drops of ethanol were added using 
Pasteur pipette before starting to grind the mixture for about 5-10 minutes.   
Cortisone:Hydrocortisone 1:2 (mc C:HC 1:2) 
36.1 mg (0.10 mmol) of cortisone and 72.6 mg (0.20 mmol) of hydrocortisone were 
placed in the mortar and ground manually. 4-5 drops of ethanol were added using 
Pasteur pipette before starting to grind the mixture for about 5-10 minutes.   
 
4.2.2. Synthesis using Supercritical CO2  
Performed by Dr Vivek Verma as a part of collaboration.  
Synthesis by gas antisolvent (GAS) method is as follows. Cortisone and 
hydrocortisone in ratios of 1:2, 1:1, and 2:1 were dissolved in 1 ml ethanol in a vial 
followed by sonication. Once the steroid solution appeared to be clear, it was 
introduced to the high-pressure vessel with magnetic stirrer plate underneath. A CO2 
cylinder was connected to a gas compressor. The pressure was set to 120 bar with 
temperature of 50 °C to ensure the supercritical condition of the CO2. The 
supercritical CO2 was then introduced to the high-pressure vessel which contained the 
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steroid solution. After all solids precipitates, the stirrer was switched off, and the 
vessel was depressurized prior to disassembling the system and collecting the yield. 
Another method called supercritical CO2 antisolvent-assisted spray drying (SADS) 
was used, with different apparatus (Long et al. 2019). In this method, CO2 was 
compressed, and the pressure and temperature were controlled. The feed of steroid 
solution was pumped into a high pressure SADS nozzle where it mixed with the 
supercritical CO2 and into the drying chamber. After all the feed solution was passed 
through the nozzle, the CO2 was depressurised and later on, the solid sample was 
harvested. This method produced more amount of samples than the GAS method, 




PXRD was measured in X’Pert Pro at 40 kV and 40 mA, Cu Kα λ = 1.54056 Å.  Scan 
range 2θ was 4°-40° with a step size of 0.0167113 degree/step and time per step of 
19.685 second/step. The sample was placed in a silicone zero background disc. 
Rietveld refinement for mixture samples was performed in Highscore! Plus (Degen et 
al. 2014).   
 
SCXRD 
A small amount of each sample was dissolved in ethanol in a vial covered by parafilm 
with few holes to facilitate slow evaporation. After several days, single crystals 
appeared. Single crystal XRD was performed in Bruker D8 Quest single crystal X-ray 
diffractometers with Mo anode and Cu anode for hydrocortisone. Measurements were 
taken at ambient temperature. The software used were Bruker APEX3 (Bruker 2016), 
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equipped with SHELXT (G. Sheldrick 2015) and SHELXL (G.M. Sheldrick 2015). 
X-SEED (Barbour 2001) was used in structure refinement.    
 
TGA 
TGA was performed in TA Instrument Q50 equipment with aluminium sample pan. 
The sample was heated to 400 °C with a rate of 10 °C/min and nitrogen gas flow rate 
of 60 ml/min. 
 
DSC 
DSC was performed in TA Instrument Q2000 equipment using hermetically sealed 
aluminium sample pan. The sample was heated to about 235 °C with a rate of 10 
°C/min and nitrogen gas flow rate of 60 ml/min. 
 
DVS 
Dynamic Vapour Sorption analysis was measured in a DVS Intrinsic (Surface 
Measurement Systems) equipment at 25 °C using HPLC grade water. The sample was 
exposed to various relative humidity (RH) in a 10% increment, from 0% RH to 90% 
and back to 0% RH. The dm/dt criterion was set to 0.005% /min.  
 
SSNMR 
Solid state NMR was performed in collaboration with Mr Simone Bordignon and 
Prof Michele Chierotti in the University of Turin.  
Solid-state NMR spectra were acquired with a Bruker Avance II 400 Ultra Shield 
instrument, operating at 400.23 and 100.63 MHz, respectively for 1H and 13C nuclei. 
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The powder samples were packed into cylindrical zirconia rotors with a 4 mm o.d. and 
a 80 L volume. A certain amount of sample was collected from each batch and used 
without further preparations to fill the rotor. 13C CPMAS spectra were acquired at room 
temperature at a spinning speed of 12 kHz, using a ramp cross-polarization pulse 
sequence with a 90° 1H pulse of 3.6 s, a contact time of 3 ms, optimized recycle delays 
ranging from 2.5 to 5.6 s and a number of scans in the range 200-6500, depending on 
the sample. For every spectrum, a two-pulse phase modulation (TPPM) decoupling 
scheme was used, with a radiofrequence field of 69.4 kHz. The 13C chemical shift scale 
was calibrated through the methylenic signal of external standard glycine (at 43.7 ppm).  
To confirm the homogeneous nature of the sample, the T1 relaxation time of 1H nuclei 
through 13C CPMAS was analysed. For the 13C T1-1H analysis of the C:HC 1:1 sample 
produced by supercritical CO2 method, 13 spectra were acquired for 320 scans with 
different relaxation delays, included in the range 0.2-60 s and calculated by the Bruker 
TopSpin 2.1 software through an exponential algorithm. 
 
Dissolution test 
The measurement was performed in sink conditions. 20 mg of each sample was 
dissolved in 1000 mL of DI water at 37 °C at 150 rpm. The sample was collected at 
minutes 1, 3, 5, 10, 15, 30, 45, and 60 and filtered through a 20 μm nylon filter. The 
HPLC used was Agilent Technologies 1260 Infinity with column Macherey-Nagel 
EC100/4.6 Nucleodur 100-5 C18ec. The mobile phase used was methanol and water 
with ratio 1:1 at 1.0 ml/min flow rate. 20 μL sample was injected into the HPLC 
system. The system and the autosampler were at ambient temperature. 
Chromatograms were recorded at 248 nm with run time of 12 minutes. Processing of 
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the chromatographic data was carried out in the software Chemstation for LC 
(Agilent Technologies).   
 
4.3. Results & Discussion  
4.3.1. Crystal Structures 
Crystallisation of the pure compounds from slow evaporation produced single 
crystals. Packing behaviour of the pure components cortisone (C) and hydrocortisone 
(HC) is different. Cortisone has Z = 4 with one molecule in the asymmetric unit, 
whereas hydrocortisone has Z = 8 with two molecules in the asymmetric unit. Bond 
lengths differ on the position 11 where hydrocortisone has CO bond length 
1.457 Å and cortisone CO bond length 1.208 Å. Slow evaporation of a solution of 
cortisone and hydrocortisone in varied ratios produced crystals suitable for single 
crystal XRD. Structure solution and refinement of three crystals (61, 62, and 63) 
reveals the product to be isomorphic to cortisone and the observed lengths of C – O 
bond on the position 11 are 1.255 Å, 1.288 Å, and 1.311 Å.
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Table 4.1. Crystallographic data of steroid crystals 
Parameters Cortisone Hydrocortisone 61 62 63 
Anode Mo Cu Mo Mo Mo 
a (Å) 7.7819(4) 10.1439(14) 7.7442(6) 7.7308(7) 7.76953(9) 
b (Å) 10.0468(5) 12.4255(16) 10.0968(8) 10.1237(9) 10.1268(11) 
c (Å) 23.6401(13) 30.496(5) 23.6750(19) 23.694(2) 23.619(3) 
α (°) 90 90 90 90 90 
β (°) 90 90 90 90 90 
γ (°) 90 90 90 90 90 
Volume (Å3) 1848.26(17) 3843.8(10) 1851.2(3) 1854.4(3) 1840.6(4) 
Space group P212121 P212121 P212121 P212121 P212121 
Formula C21 H28 O5 C21 H30 O5 C21 H28 O5 C21 H28 O5 C21 H28 O5 
ρ (g cm-3) 1.295 1.242 1.296 1.296 1.306 
Z, Z’ 4, 1 8, 2 4, 1 4, 1 4, 1 
Temperature (K) 296  300  296  296  296  
μ (mm-1) 0.091 0.713 0.091 0.091 0.092 






Figure 4.3. Cortisone 
 
 
Figure 4.4. Crystal of mixed C:HC with bond length of 1.255 Å   
 
 
Figure 4.5. Hydrocortisone 
 
4.3.2. PXRD and Rietveld Refinement 
The bulk synthesis of C-HC solid solutions were attempted with manual grinding of 
the reagents in a 2:1, 1:1, and 1:2 ratio. Qualitative analysis by PXRD suggests that 
the mechanochemical method produces physical mixtures rather than solid solution. 
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Milling the cortisone and hydrocortisone in 1:1 ratio with few drops for ethanol in a 
10 ml milling jar with one ball (10 mm) at 25 Hz for 40 minutes resulted in powder 
with PXRD pattern similar to the physical mixture. Rietveld refinement was 
performed against the pure cortisone and hydrocortisone crystal structures, 
determining the weight fraction of the samples (Table 4.2). Notably, the results of 
such refinement coincides with those expected for a physical mixture of the reagents.   
 
Figure 4.6. PXRD patterns of the cortisone - hydrocortisone in mixed composition produced 
by mechanochemical synthesis (mc) and gas antisolvent (GAS) 
 
 
Table 4.2. Rietveld refinement of mechanochemical samples 
Sample 
Weight fraction (%) Weight fraction (%) 
Calculated Found 
C HC C HC 
mc C:HC 1:2 33.18 66.82 32.2(5) 67.8(3) 
mc C:HC 1:1 49.86 50.14 48.7(4) 51.3(3) 
mc C:HC 2:1 66.58 33.42 65.4(3) 34.6(2) 
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A further solid solution synthesis was attempted with the aid of supercritical CO2 as 
antisolvent (GAS). In order for CO2 to be supercritical, the minimum temperature and 
pressure is 37 °C and 79 bar respectively. The synthesis used 50 °C and 120 bar to 
reach supercritical condition of CO2. The same set of ratios of cortisone and 
hydrocortisone were used in this synthesis. The yield of the process is white 
microcrystalline powder. The PXRD patterns of the samples from the GAS method 
are different from those of the manual grinding. The PXRD pattern of product from 
the other method, SADS, is similar to that of the GAS method (Figure C.1 in 
Appendix C). In fact, the samples produced with the aid of supercritical CO2 is 
homogeneous rather than the physical mixture. Rietveld refinements of the PXRD for 
the products of supercritical CO2 method are obtained for the ratio C:HC  1:1 and 2:1, 
using cortisone as a structural model, suggests that the samples have a homogeneous 
distribution of the two components in a cortisone-like phase.  
 
4.3.3. SSNMR 
To verify further this result, solid state NMR was performed in collaboration with Mr 
Simone Bordignon and Prof Michele Chierotti of Univerity of Turin.  
The 13C CPMAS NMR spectra of pure cortisone, pure hydrocortisone, and 2:1, 1:1 
and 1:2 cortisone:hydrocortisone obtained from the supercritical CO2 method (Figure 
4.7) recall that of pure cortisone, but with apparent differences, especially in the 
number of signals. A further comparison, with an overlay of the spectra of the pure 
components and the 1:1 solid solution, shows the differences, in terms of chemical 
shift, between the set of signals in the spectrum of the solid solution and those of both 
the pure end-members (Figure 4.8). These are more pronounced for hydrocortisone. 
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This can be traced back to the statistically homogeneous nature of the mixture, in 
accordance with it being a solid solution. 1H T1 relaxation measurements (acquired 
through 13C) were performed on the C:HC 1:1 sample from the supercritical CO2 
method, further confirming this: indeed, the 1H T1 values are the same for each 13C 
signal, indicating active spin diffusion processes, i.e. homogeneous domains over a 




Figure 4.7. 13C (100 MHz) CPMAS spectra of pure cortisone (C), pure hydrocortisone (HC) 
and three C:HC solid solutions (ratios = 2:1; 1:1; 1:2), acquired at room temperature with a 
spinning speed of 12 kHz 
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Figure 4.8. Overlay of the 13C CPMAS spectra of the  (in green), pure cortisone (in red) and 









Figure 4.10. Water sorption of antisolvent supercritical CO2 samples 
 
At 80% relative humidity, the pure compounds have lower water uptake compare to 
the mixed composition samples (Figure 4.9). The highest water uptake at 80% RH is 
0.24% for mechanochemical samples C:HC 1:2 and 2:1 as in Figure 4.9. 
Nevertheless, overall water uptake at 80% RH and 25°C was still below 2%. Thus 
they are not considered as hygroscopic. This behaviour is expected of a lipid family. 
European Pharmacopoeia (2013) classified material as hygroscopic when the increase 
in mass is less than 15% and equal to or greater than 2%. The samples from 
antisolvent supercritical CO2 method (Figure 4.10), which are solid solutions, have 




Dissolution profiles of the samples produced by mechanochemical and supercritical 
CO2 are measured. The dissolution profile of cortisone-hydrocortisone in 1:1 physical 
mixture is similar to that of the mechanochemical sample 1:1 (Figure 4.11). This 
supports the hypothesis that the mechanochemical method produces a physical 
mixture.  The cortisone dissolution profiles (Figure 4.12) from samples produced by 
supercritical CO2 method suggest that mixing cortisone with hydrocortisone as solid 
solution can change the dissolution profile of cortisone. The pure cortisone used in 
this experiment was given the same treatment as the mixed composition. Within 10 
minutes, 95% dissolution is achieved in the solid solution C:HC with 2:1 ratio sample 
compared to 56% dissolution for the pure cortisone. Solid solution samples C:HC 
with ratios 1:1 and 1:2 reach 86% dissolution after 15 minutes, while pure cortisone 
reach 63% dissolution. All samples reach nearly 100% within 45 minutes. Although it 
may seem that the dissolution profile can be improved, it needs to be confirmed by 
the measurement of particle size distribution and morphology of the solid solution 
samples produced by supercritical CO2 synthesis. This way, the improved dissolution 








Figure 4.12. Cortisone dissolution profile of the sample produced by supercritical method  
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4.3.6. Particle Size 
The particle size of the mechanochemical samples was measured to observe whether 
it affects the water uptake behaviour. Particles with smaller size have a bigger surface 
area. Therefore they can absorb more water than particles with bigger size. 
Considering the CE (circle equivalent) diameter, as shown in Table 4.3, the particle 
size effect on the water uptake behaviour and dissolution profile (Figure 4.13) on the 
mechanochemical samples is negligible.  
 
Table 4.3. Particle size by number distribution 











mc C  4.4 1.03 2.75 9.65 4.61 
mc C:HC 2:1  4.24 1.16 2.91 8.62 4.32 
mc C:HC 1:1  2.31 0.79 1.46 4.57 2.59 
mc C:HC 1:2  2.61 0.87 1.68 5.34 2.73 





Figure 4.13. Cortisone composition with respect to the change in mass and particle size D50 




Besides suggesting similarity of the shapes and sizes are important for forming solid 
solutions by two or more components, Kitaigorodsky in his book Molecular Crystals 
and Molecules also mentions that “they must not only have an identical space group 
and the same number of molecules in the unit cell, but also exhibit a similar packing 
of molecules”(Kitaigorodsky 1973). Here, cortisone and hydrocortisone have the 
same space group, but differ in the lattice parameters and the number of molecules in 
the unit cell. Therefore solid solution should not form in this system. Slow 
evaporation of cortisone and hydrocortisone in different compositions produced 
single crystals. Crystal structures of the mixed composition samples solved from 
single crystal X-ray diffraction show differences in the bond length at position 11. 
Synthesis by manual grinding with the aid of ethanol produce physical mixtures 
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rather than solid solution as indicated by PXRD patterns. In contrast, the products 
from antisolvent supercritical CO2 exhibit different PXRD patterns, which suggest 
single phase of solid solution.  
In conclusion, this work demonstrates that two non-isostructural organic compounds 
can form solid solutions and the possibility of a solid solution consists of a drug 
prodrug material. The ability of known methods to produce solid solution are 
different. In fact, the physical properties and phase(s) are very dependent on the 
synthesis method. Mechanochemical synthesis produced physical mixture while 
synthesis with the aid of supercritical CO2 produced solid solution. This finding 
suggests that the attempt to form solid solution needs to be done by performing more 
than one method. The solid solution samples from the supercritical CO2 method 
exhibit different dissolution profiles in comparison to the pure cortisone as 
demonstrated in sample ratio C:HC 2:1 which reach 95% dissolution after 10 minutes 
while the pure cortisone only about 56%. However, whether the dissolution is really 
improved must be verified by particle size distribution. 
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Chapter 5  
Cisplatin and Its Analogues 
 
5.1. Introduction 
Cisplatin (cis-dichlorodiammeplatinum(II), cis-[Pt(NH3)2Cl2]), one of the most 
effective and long-known chemotherapy drugs, is a coordination complex with 
platinum. Cisplatin was first synthesized in the 1840s by Michele Peyrone. He was 
trying to synthesise Magnus’ green salt [Pt(NH3)4][PtCl4], the first discovered 
platinum-ammine salt, by adding excess ammonia to an acidified PtCl2 solution when 
he observed the yield, one being green (Magnus’ green salt) and one being yellow. 
Since Magnus’ green salt is insoluble in hydrochloric acid, separation of the two was 
managed, and the filtrate yield a yellow precipitate [Pt(NH3)2Cl2] (Kauffman et al. 
2010).  
 
Magnus’ green salt 
 
                cisplatin 
 
Figure 5.1. Magnus' green salt and cisplatin 
 
Cisplatin contributed a part when Alfred Werner established the theory of 
coordination chemistry (Alderden et al. 2006). Werner was known to be concerned 
about the platinum(II) and platinum(IV) complexes; in the 1890s he studied the 
reaction of cis-[Pt(II)(NH3)2Cl2] and trans-[Pt(II)(NH3)2Cl2] and proposed a square 
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planar configuration for platinum(II) and an octahedral configuration for 













Figure 5.2. Carboplatin, oxaliplatin, nedaplatin, heptaplatin, and lobaplatin. 
 
The use of cisplatin as drugs started with Rosenberg’s experiment in the 1960s on the 
effect of electric field on cell division. Serendipitously, he discovered the platinum 
compound inhibits cell division but not cell growth (Rosenberg et al. 1965). The 
research of antitumour activity of several platinum complexes continued. Cisplatin 
(cis-dichlorodiammeplatinum(II), cis-Pt(II)(NH3)2Cl2) was synthesised as a model for 
active neutral platinum(IV) and platinum(II) complexes. Stereospecificity was 
observed, which also had occurred in the bacterial test: the cis-isomer being the active 
107 
one (Rosenberg 1999). In 1978 FDA approved cisplatin for metastatic ovarian and 
testicular cancer treatment. Other widely approved platinum-based anticancer drugs 
are carboplatin and oxaliplatin (Wilson and Lippard 2014), some others only 
approved in certain country such as nedaplatin (Japan; Shionogi & Co. Ltd), 
heptaplatin (South Korea; SK Pharma), and lobaplatin (China) (Kapdi and Fairlamb 
2014).   
As chemotherapy drug, cisplatin acts on the cancer cells by triggering apoptosis (cell 
death). Nephrotoxicity as dose-limiting toxicity and other side effects remain 
challenges in cisplatin therapy, led to the attempt to develop more effective and less 
toxic platinum analogues with the hypothesis that less labile leaving group could 
change the toxicity of cisplatin as observed in carboplatin. This substitution with 
more stable ligands diminished renal effects but still retained the anti-tumour activity 
(O'Dwyer et al. 1999). The attempt to synthesis analogue complexes using palladium 
is also triggered by the nephrotoxicity of cisplatin, leading to findings that selected 
cis palladium organometallics could behave like the known platinum drugs 
(Newkome et al. 1980).  Graham and Williams found that cis-[Pd(NH3)2Cl2], 
trans-[Pd(NH3)2Cl2], and cis-[Pd(NH3)2Cl4], have anticancer properties (Graham and 
Williams 1979).  
Some investigations were focused on the iodide analogue of cisplatin. A platinum(II) 
complex, cis-diiodido diisopropylamine platinum(II) is reported to have anti-
proliferative activity (Messori et al. 2010). cis-[Pt(NH3)2I2] has cytotoxic effects that 
are comparable or greater than cisplatin in four representative cell lines and produced 
a kind of DNA damage similar to cisplatin (Marzo et al. 2015). This finding 
motivated the group to investigate the biological profile of the dibromido analogue of 
cisplatin cis-[Pt(NH3)2Br2]. The compound shows the cytotoxic effect is comparable 
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to cisplatin during cellular studies, and it triggers apoptosis in FLG 29.1 leukaemia 
cells (Marzo et al. 2016). It is also reported that cis-[Pt(NH3)2I2] has higher reactivity 
than cisplatin when tested with oligonucleotides, quite the opposite of what was 
believed (Musumeci et al. 2016).   
Milburn and Truter (1966) reported cisplatin obtained by Ramberg’s method with 
unit cell parameters of a = 6.75 Å, b = 6.55 Å, c = 6.23 Å, α = 92.2°, β = 84.6°, 
γ = 110.7° and space group 𝑃1̅ at 120 ± 5 K.  Ting et al. (2010) used DMF to 
recrystallise cisplatin. They reported that β-form cisplatin transformed into the α-form 
at low temperatures, hence the α-form was measured at 100 K. The data corresponded 
with those reported by Milburn, meanwhile the β-form was measured at 220 K and 
has a larger unit cell with the b axis doubled that of the α-form. The α-form 
crystallises in triclinic space group 𝑃1̅, a = 6.2424(2) Å, b = 6.5087(2) Å, 
c = 6.7451(2) Å, α = 69.896(1)°, β = 83.710(1)°, γ = 87.348(1)°, V = 255.795(14) Å3, 
Z= 2. The β-form crystallises in triclinic space group 𝑃1̅, a = 6.2846(2) Å, 
b = 13.4990(4) Å, c = 6.6839(2) Å, α = 69.444(1)°, β = 85.586(1)°, γ = 82.2291)°, 
V = 525.79(3) Å3, Z= 4. The transplatin structure was reported by Porai-Koshits 
(1954). Meanwhile, the crystal structures for the analogue complexes, 
cis-[Pt(NH3)2I2] and cis-[Pt(NH3)2Br2] are yet to be reported. 
Kirik and his group reported the structure of some palladium complexes using X-ray 
powder diffraction method, cis-[Pd(NH3)2Cl2] (Kirik et al. 1996; Soloviov et al. 
1996), trans-[Pd(NH3)2Cl2] (Kirik et al. 1996), β-trans-[Pd(NH3)2Cl2] (Kirik et al. 
1996), cis-[Pd(NH3)2Br2] (Kirik et al. 2000), trans-[Pd(NH3)2Br2] (Kirik et al. 2000), 
β-trans-[Pd(NH3)2Br2] (Kirik et al. 2000), cis-[Pd(NH3)2I2] (Kirik et al. 2000), and 
β-trans-[Pd(NH3)2I2] (Kirik et al. 2000). Study of cis-[Pd(NH3)2Cl2] found that it 
does not have anti-tumour activity (Butour et al. 1997). 
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The most widely used method for the synthesis of cisplatin is the one developed by 
S.C. Dhara (Dhara 1970; Wilson and Lippard 2014).  As depicted in Figure 5.3, an 
aqueous [PtCl4]2- is treated with KI thus converted to [PtI4]2-, then the addition of 
ammonium hydroxide yields a yellow precipitate cis-[Pt(NH3)2I2]. The latter is 
reacted with AgNO3 in aqueous solution, resulting in cis-[Pt(NH3)2(OH2)2]2+. 
Treatment with excess chloride ion will precipitate yellow crystals of 
cis-[Pt(NH3)2Cl2]. Kurnakow test is used to distinguish between the cis- and trans- 
isomers of [Pt(NH3)2Cl2] by adding thiourea (Alderden et al. 2006). Reaction of 
thiourea with cisplatin will produce a yellow solution. The reaction of thiourea with 
transplatin will produce insoluble white compound of trans-[Pt(NH3)2(Th)2]Cl2.  
 
Figure 5.3. Schematic of cisplatin synthesis (Alderden et al. 2006) 
 
As a part of our research on solid solutions of drugs, the synthesis and 
characterisation of cisplatin and its analogues (cis-[Pt(NH3)2I2], cis-[Pt(NH3)2Br2], 
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cis-[Pd(NH3)2I2], cis-[Pd(NH3)2Cl2], and cis-[Pd(NH3)2Br2])  was attempted. 
Cisplatin is a highly toxic chemotherapy drug. Solid solution opens the possibility to 
modify the properties, in this case, to reduce the toxicity of the drug. The intention 
was to make solid solutions of cisplatin and its analogues, such as cis-
[M(NH3)2ClxBr1-x] where M = Pt or Pd, and cis-[PtxPd1-x(NH3)2X2] where X = Cl, Br 
or I, 0 ≥ x ≥ 1. Characterisation of samples would essentially follow to observe the 
fine-tuning properties of solid solutions. Since cis-[Pt(NH3)2I2] and cis-[Pt(NH3)2Br2 
have been studied for their cytotoxic activities (Marzo et al. 2015; Marzo et al. 2016; 





K2PtCl4 (Alfa Aesar), K2PdCl4 (Alfa Aesar), KI (Sigma Aldrich), KBr (Merck 
KGaA), KCl (AppliChem), AgNO3 (Sigma Aldrich), NH4OH (Sigma Aldrich) were 
used without further purification. 
 
5.2.2. Synthesis 
The complexes were prepared using Dhara’s method as depicted in Figure 5.3 with 
necessary modifications to produce the desired crystals. The reported methods for cis-
[Pt(NH3)2I2] (Marzo et al. 2015) and cis-[Pt(NH3)2Br2] (Marzo et al. 2016) are also 
based on Dhara’s method. Cis- [Pt(NH3)2Br2] and cis-[Pd(NH3)2Br2] were obtained 
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by adding excess bromide ion instead of chloride. In the case of palladium analogues, 
the starting material K2PtCl4 was changed to K2PdCl4. 
 
[Pt(NH3)2I2] (71) 
K2PtCl4 (0.5 mmol, 207.6 mg) was weighed and dissolved in water. While being 
stirred, a solution of KI (excess amount; 5 mmol, 830 mg) was added to the solution. 
The colour changed into dark brown immediately after KI was added. NH3 (1 mmol) 
was added dropwise, and yellow precipitates should be formed. The addition of NH3 
was continued until the solution becomes colourless. The precipitates were filtered 
and air-dried. The yellowish solids from this reaction were not suitable for single 
crystal XRD. Recrystallisation to obtain single crystal was unsuccessful. PXRD of the 
solid was measured instead. 
 
Figure 5.4. Product from synthesis of cis-[Pt(NH3)2I2]. 
 
Cisplatin cis-[Pt(NH3)2Cl2] (72) 
Solids obtained from reacting K2PtCl4 with KI and NH3 (71)  (0.3 mmol, 145.4 mg) 
was weighed and dissolved in water, forming a yellow suspension. AgNO3 (0.6 
mmol, 102.04 mg) was dissolved in water and added into the suspension while 
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stirring. After filtration, the filtrate was mixed with KCl solution (0.6 mmol, 45.5 mg) 
to produce yellow crystals of cis-[Pt(NH3)2Cl2].  
 
Figure 5.5. Yellow crystals of cis-[Pt(NH3)2Cl2] 
 
[Pt(NH3)2Br2] (73) 
(71) (0.25 mmol, 121.1 mg) was weighed and dissolved in water, forming a yellow 
suspension. AgNO3 (0.5 mmol, 84.93 mg) was dissolved in water and added into the 
suspension while stirring. After filtration, the filtrate was mixed with KBr solution 
(0.5 mmol, 60.5 mg) to produce dark orange of cis-[Pt(NH3)2Br2]. 
 
Figure 5.6. Crystals from the synthesis of cis-[Pt(NH3)2Br2] 
 
[Pd(NH3)2I2] (74) 
K2PdCl4 (0.5 mmol, 163.4 mg) was weighed and dissolved in water. While being 
stirred, a solution of KI (excess amount; 5 mmol, 830 mg) was added to the solution. 
The KI solution was mixed with K2PdCl4 solution while being stirred. The colour 
changed into dark brown immediately after KI was added. NH3 (1 mmol) was added 
dropwise, and precipitates should be formed. The addition of NH3 was continued 
until the solution becomes colourless. The precipitates were filtered using a sintered 
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funnel and air-dried. The reaction was able to produce dark brown solids. 
Recrystallisation for the compound to yield good quality single crystals was 
unsuccessful. 
 
Figure 5.7. Product from the attempt to synthesis cis-[Pd(NH3)2I2] 
 
[Pd(NH3)2Cl2] (75) 
(74) (0.1 mmol, 39.9 mg) was weighed and dissolved in water, forming a yellow 
suspension. AgNO3 (0.2 mmol, 33.9 mg) was dissolved in water and added into the 
suspension while stirring. After filtration, the filtrate was mixed with KCl solution 
(0.2 mmol, 14.9 mg). 
 
[Pd(NH3)2Br2] (76) 
(74) (0.2 mmol, 79.6 mg) was weighed and dissolved in water, forming a yellow 
suspension. AgNO3 (0.4 mmol, 69 mg) was dissolved in water and added into the 
suspension while stirring. After filtration, the filtrate was incubated with KBr solution 
(0.4 mmol, 48.9 mg). When KBr solution was added into the supernatant and mixed, 
the solution colour immediately changed into yellowish colour. No crystals were 




Powder X-Ray Diffraction 
PXRD was conducted in APXRD Proto Manufacturing using Cu-Kα radiation (λ = 
1.5406 Å) at 30 kV and 20 mA power within 2θ range of 5° – 40° with an aluminium 
sample holder. 
 
Single Crystal X-Ray Diffraction 
Single crystal XRD was conducted in Bruker D8 Quest with copper anode with 
APEX3 software (Bruker 2016) with integrated SHELXT (G. Sheldrick 2015) for 
structure solution. Structure refinement was performed in X-SEED (Barbour 2001).  
 
5.3. Results and Discussion 
5.3.1. [Pt(NH3)2I2] (71) 
There is no crystal structure reported for cis-[Pt(NH3)2I2] in CSD (Groom et al. 2016) 
(Cambridge Structural Database) or COD (Grazulis et al. 2009) (Crystallography 
Open Database), except for crystal structure of DMA solvate of cis-[Pt(NH3)2I2] that 
is reported (Raudaschl-Sieber et al. 1986) (CSD reference code DUXDAB). PXRD 
were measured for the obtained solids (Figure 5.8). Therefore it is challenging to 




Figure 5.8. PXRD pattern of dried sample 71 
 
5.3.2. Cisplatin cis-[Pt(NH3)2Cl2] (72) 
Dhara’s method of cisplatin synthesis to make 72 resulted in yellow needle-like 
crystals which were suitable for single crystal X-ray diffraction (Table 5.1).   
 




Table 5.1. Crystallographic data for cis-[Pt(NH3)2Cl2]    
Parameters 72 
Anode Cu 
Space group 𝑃1̅ 
Formula Cl2 H6 N2 Pt 
a (Å) 6.2250(8) 
b (Å) 6.5790(8) 
c (Å) 6.8104(9) 
α (°) 70.104(7) 
β (°) 84.550(7) 
γ (°) 87.433(7) 
Volume (Å3) 262.32(6) 
Mr 300.06 
ρ (g cm-3) 3.799 
μ (mm-1) 58.12 
Z 2 
R gt (n. refl.) 0.0860 (807) 
Temperature (K) 163  
 
According to the structure solution, 72 is indeed cis-[Pt(NH3)2Cl2]. There are two 
molecules of cisplatin in a unit cell. The NH3 groups and the Cl atoms are 
alternatingly stacked along the c axis. The central Pt atoms also present in staggered 
arrangement along c. The crystals then were carefully ground into powder and 
measured in the PXRD. The comparison of PXRD pattern and calculated pattern from 
the solved crystal structure is in Figure 5.10, which shows that the PXRD pattern of 
the bulk crystal is not similar to the calculated pattern from the single crystal. The 




Figure 5.10. PXRD pattern of ground crystal 72 compared to calculated pattern from single 
crystal 72 
 
5.3.3. [Pt(NH3)2Br2] (73) 
Modified Dhara’s method resulted in dark orange needle-like crystals that was 
suitable for single crystal X-ray diffraction (Table 5.2).  Compound 73 is confirmed to 
be cis-[Pt(NH3)2Br2] according to the crystal structure solution and refinement. There 
are four molecules of cis-[Pt(NH3)2Br2] in the unit cell. There is no reported crystal 
structure for this compound in CSD or COD. The compound is stacked alternatingly. 


















Table 5.2. Crystallographic data for cis-[Pt(NH3)2Br2]   
Parameters 73 
Anode Cu 
Space group 𝑃21/𝑐 
Formula Br2 H6 N2 Pt 
a (Å) 6.9478(2) 
b (Å) 12.6879(3) 
c (Å) 6.5327(2) 
α (°) 90 
β (°) 96.919(1) 
γ (°) 90 
Volume (Å3) 571.68(3) 
Mr 388.98 
ρ (g cm-3) 4.519 
μ (mm-1) 61.118 
Z 4 
R gt (n. refl.) 0.0705 (965)  
Temperature (K) 297  
 
5.3.4. [Pd(NH3)2I2] (74) 
There are two structures reported on [Pd(NH3)2I2] (Kirik et al. 2000): 
cis-[Pd(NH3)2I2] in orthorhombic 𝑃𝑏𝑐𝑎 and β-trans-[Pd(NH3)2I2] also in 
orthorhombic 𝑃𝑏𝑐𝑎. The sample was measured in PXRD. The result does not match 
with calculated reference patterns of the cis- and the β-trans forms. The available data 
cannot verify whether the resulting product is indeed cis-[Pd(NH3)2I2]. 
 
5.3.5. [Pd(NH3)2Cl2] (75) 
Only very little amount of the product from the reaction recovered. There are three 
forms of [Pd(NH3)2Cl2] reported (Kirik et al. 1996; Soloviov et al. 1996). 
Cis-[Pd(NH3)2Cl2] crystallised in triclinic 𝑃1, trans-[Pd(NH3)2Cl2] in 𝑃1̅, and 
β--rans-[Pd(NH3)2Cl2] in 𝑃𝑏𝑐𝑎. Their crystal structures were determined from 
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powder X-ray diffraction and the data is deposited in ICDD (International Centre for 
Diffraction Data). PXRD of the sample does not match the reference pattern.  
 
5.3.6. [Pd(NH3)2Br2] (76) 
Characterisation were not carried out since the reaction produced no solids.  
 
5.3.7. General Discussion 
Revisiting the crystal structures of the obtained products, cisplatin is crystallised in 
𝑃1̅ space group with lattice parameters of a = 6.2250(8) Å, b = 6.5790(8) Å, 
c = 6.8104(9) Å and cis-[Pt(NH3)2Br2] in 𝑃21/𝑐  with a = 6.9478(2) Å, 
b = 12.6879(3) Å, c = 6.5327(2) Å. These two complexes are not isostructural. So far 
there is no report on the structure and no single crystal managed to grow in order to 
solve the structure of cis-[Pt(NH3)2I2], hence it is rather challenging to confirm that 
the solid obtained from the synthesis is cis-[Pt(NH3)2I2]. In the palladium complexes, 
cis-[Pd(NH3)2Cl2] is reported to crystallise in 𝑃1  with a = 6.3121(2) Å, b = 6.4984(2) 
Å, c = 3.3886(1) Å (Kirik et al. 1996). cis-[Pd(NH3)2Br2] is reported to crystallise in 
𝑃𝑏𝑐𝑎  with a = 13.3202(7) Å, b = 12.7223(6) Å, c = 7.05854(3) Å (Kirik et al. 2000). 
cis-[Pd(NH3)2I2] is reported to crystallise in 𝑃𝑏𝑐𝑎 with a = 13.9060(8) Å, b = 
13.5035(8) Å, c = 7.5050(4) Å (Kirik et al. 2000). Considering these structures, cis-
[Pt(NH3)2Cl2] is not isostructural to cis-[Pd(NH3)2Cl2] and cis-[Pt(NH3)2Br2] is not 
isostructural to cis-[Pd(NH3)2Br2]. Even though cis-[Pd(NH3)2Br2] is in the same 
space group as cis-[Pd(NH3)2I2], the lattice parameter b is about 0.8 Å shorter in cis-
[Pd(NH3)2Br2]. Therefore, there is no pair of isostructural crystals in the complexes.  
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The aqueous method used in this work only yields a small amount of product. The 
PXRD patterns of the samples are also not similar to the calculated patterns from the 
single crystals, indicating that there might be impurities in the samples. The low yield 
of the reaction hinders further characterisation. The method employed to obtain the 
palladium analogues was derived from the literature (Kirik et al. 1996; Soloviov et al. 
1996; Kirik et al. 2000) involving mechanochemistry and using different starting 
materials. For instance, to obtain cis-[Pd(NH3)2Cl2], the reaction as described by 
Soloviov et al. (1996) is  
[Pd(NH3)2C2O4] + 2 HCl  cis-[Pd(NH3)2Cl2] + H2C2O4 
In that method, the starting material is cis-[Pd(NH3)2C2O4] and depending on the 
desired result HCl, HI, or HBr is added in excess before grinding. However, platinum 
analogue of cis-[Pd(NH3)2C2O4] needs to be obtained if the platinum complexes are 
to be synthesised in a similar fashion. The mechanochemistry will result in powder 
form, which will be likely to produce more samples than the aqueous method. 
However, there is a side product of H2C2O4 that needs to be separated from the 
complex. It will require purification and recrystallisation to obtain single crystals to 
solve the structures of the unreported complexes. Considering these factors and cost, 
the mechanochemical pathway is not pursued to attain the complexes, as well as the 
attempt to form a solid solution with the complexes. 
 
5.4. Conclusion 
The solution synthesis performed as modified Dhara’s method is able to produce 
cisplatin crystals and its dibromo analogue. The method so far is not working well to 
produce the palladium analogue complexes. Crystal structures for the two complexes 
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were solved. Cisplatin synthesised in this work is more similar to the reported α-form. 
The new structure obtained in this work that has not been reported in the CSD or 
COD database is cis-[Pt(NH3)2Br2], which is non-isostructural to cisplatin. Cis- 
[Pt(NH3)2Br2] also differs from cisplatin in terms of packing arrangement. The 
system would be a very interesting experiment considering the dissimilarities 
between cisplatin and cis-[Pt(NH3)2Br2. However, the synthesis yields only a small 
amount of crystals. For the other analogues, it is problematic to obtain single crystals 
for the intended compounds using the aqueous methods. Taking into account on the 














Chapter 6  
Conclusion 
 
Solid solutions are solid phases comprising two or more components which can be 
changed or mixed in varied ratio (Lusi 2017). Such feature presents solid solution to 
the possibility of fine-tuning properties with composition.  Hume-Rothery (1926) 
summarised some empirical conditions for the formation of solid solutions, which 
include: 1) structures, 2) atomic size, and 3) valence similarity. Kitaigorodsky 
suggests that the similarity of shapes and sizes of the molecular components, as well 
as their ability to form specific H-bonds, are necessary for two components to form 
solid solution crystals, including packing factors and symmetry for a continuous 
series of solid solution (Kitaigorodsky 1973; Kitaigorodsky 1984). Contrary to the 
Kitaigorodsky suggestions, a system of acridine and phenazine was shown to have 
almost complete miscibility despite being non-isostructural and have polymorphs 
(Schur et al. 2015). This was justified with the structural flexibility affecting the 
formation of solid solutions, suggesting that Kitaigorodsky’s concept and Hume-
Rothery rules might require a revision. As solid solutions of pharmaceuticals are 
rather understudied, this work used some compounds as representative for active 
pharmaceutical ingredients such as lithium, cortisone and hydrocortisone. The 
compounds have structures that are suitable to test the guidelines mentioned above on 
different classes of crystals. 
In an attempt to form solid solutions with lithium and sodium, the isoorotate and 
citrate salt forms were used. Lithium isoorotate monohydrate and sodium isoorotate 
monohydrate have similar unit cells and the same space group. They exhibit what has 
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been defined as pseudo-isomorphism (Chao and McCullough 1961; d’Agostino et al. 
2014). The lithium coordinates to five oxygens and sodium to six oxygens. Also, the 
difference in atomic sizes of lithium and sodium is bigger than what prescribed by 
Hume-Rothery. Lithium and sodium have crystal radii of 0.88 Å and 1.16 Å, 
respectively (Shannon and Prewitt 1969); the difference between the two atoms is 
more than 15%. Nevertheless, in hydrate molecular salts of isoorotates, lithium and 
sodium formed the solid solutions Li1-xNaxIOR·H2O. Lithium dihydrogen citrate and 
sodium dihydrogen citrate are an isomorphous pair (Glusker et al. 1965), which 
would enable the formation of solid solution. However, that is not observed in this 
work. Similarly, manual grinding of lithium carbonate and sodium carbonate in 
various ratios with one equivalent of citric acid resulted in physical mixtures. Perhaps 
this is a consequence of the concomitant appearance of the more stable polymorph or 
the monohydrate forms of lithium dihydrogen citrate, which hinder the formation of 
solid solution. If that was the case, it appears that in this system solid solutions cannot 
be used to control polymorphism as demonstrated by solid solutions of Co/Zn 
coordination polymer (Adams et al. 2010a). 
Lithium is also studied as coordination polymers in this work. In the 
{Li[MBNZ]x[BNZ]1-xPro}n system, solid solution forms to a certain extent despite the 
non-isostructural nature of the parent compounds. In this case, the solid solution 
adopts the structure of the most abundant component. A complete solid solution can 
form as observed in system {Li2[SUC]x[MAL]1-x}n. However, lithium tends to be 
hygroscopic. In the lithium coordination polymers, the solid solutions tend to be more 
hygroscopic than the parent compounds. The {Li2[SUC]x[MAL]1-x}n system has more 
linear behaviour than {Li[MBNZ]x[BNZ]1-xPro}n. This suggests that characteristic 
variation can happen within a class of material. This behaviour is speculated due to 
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lattice energy. In the {Li[MBNZ]x[BNZ]1-xPro}n, they are less stable due to bigger 
lattice energy, thus requires less energy for hydration. The solid solution of isoorotate 
Li1-xNaxIOR·H2O are not hygroscopic, which makes them suitable for pharmaceutical 
application.  
Due to the lack of isomorphicity and different H-bond capability, solid solutions of 
cortisone and hydrocortisone system are not expected to form. Indeed, manual 
grinding with the aid of ethanol produced physical mixtures, as confirmed by 
Rietveld refinement. On the other hand, crystals with mixed cortisone and 
hydrocortisone have bond lengths variations at position 11, where the cortisone has a 
carbonyl group and hydrocortisone has a hydroxyl group. Moreover, synthesis with 
supercritical CO2 as antisolvent revealed that the synthesis produces solid solution, as 
verified by PXRD and solid-state NMR. This finding implies that isostructurality and 
H-bond patterns are not always necessary, as also demonstrated in the 
{Li[MBNZ]x[BNZ]1-xPro}n system and that particular method of synthesis can help to 
break the limitation, as in GAS method using supercritical CO2. Besides the structural 
considerations, the properties of solid solutions were tested. Moisture stability is 
crucial concerning the storage of materials as the properties can change. The samples 
from the cortisone-hydrocortisone system are not hygroscopic, which is expected as 
they are of lipid class. 
The syntheses of cisplatin cis-[Pt(NH3)2Cl2] and its analogues were performed using 
Dhara’s method (Dhara 1970) with modifications when necessary. The process, 
however, did not work as expected to yield pure materials for making solid solutions 
of metal complexes. Despite this predicament, a new structure, cis-[Pt(NH3)2Br2], is 
obtained.    
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In conclusion, the similarity of the shape and size is not always necessary to the 
formation of solid solutions. The isostructurality or isomorphism is also not the sole 
factor in determining the formation of a solid solution. It is also necessary to consider 
if a more stable form of a compound exists. A transformation of one compound into a 
more stable form might hinder solid solution formation, as evident in the dihydrogen 
citrate case. As demonstrated in series {Li[MBNZ]x[BNZ]1-xPro}n and in cortisone-
hydrocortisone system, non-isostructural pair of compounds can form solid solution. 
The difference in atom size, in this case, the crystal radii, of lithium and sodium is 
bigger than what is suggested by Hume-Rothery. The solid solution Li1-xNaxIOR·H2O 
can be formed despite the pseudo-isomorphism nature, and the structure can 
accommodate the size differences as well as geometrical arrangement. The findings in 
this work suggest that such empirical rules or guidelines do not limit the formation of 
solid solution. Those seem to be too restrictive and may be outdated. The Hume-
Rothery rules are based on studies that were performed a long time ago (about a 
century ago) on narrow sets of alloys and ceramics. The time has passed, and 
technology has improved since then. It is not expected for the coordination polymers 
and molecular solids to still follow these rules. It is evident in this work that the 
physical properties and the phase(s) are very dependent on the method of preparation. 
This work also demonstrates that solid solutions of active pharmaceutical ingredients 
can be developed for a whole range of materials to provide tuneable properties, for 





In terms of future work, experiments with several systems and perhaps different 
synthetic methods to form solid solutions would be beneficial to obtain more 
observations and to explore if deviations from the guidelines as suggested by Hume-
Rothery and Kitaigorodsky occur. Hopefully, this would give more insights in the 
mechanism or certain requirements regarding solid solution formations.  
If a straightforward method of obtaining certain pairs of metal complexes is available, 
a study of solid solutions in metal complexes can be carried out considering the metal 
complex part was ceased in this work. It may be worth a try to use a different method, 
for instance, synthesis with the aid of supercritical CO2, to be applied in the 
dihydrogen citrate system. The first aim will be to observe which form of sodium 
dihydrogen citrate is produced. If it affords the form I, the next objective is to to 
make lithium dihydrogen citrate in anhydrous form. If it is possible, then the next 
target is the attempt to make solid solution of lithium dihydrogen citrate and sodium 
dihydrogen citrate.  
Other methods of synthesis can also be performed on known series of solid solutions, 
i.e. isoorotate system Li1-xNaxIOR·H2O which was done by mechanochemistry in this 
work, to confirm that same solid solutions can be obtained from more than one 
method. Performing the dissolution test and scale-up of the isoorotate system will 
complement the study too, since this work mostly dealing with synthesis in small 
scale. Other characterisations related to pharmaceutical application, e.g. stability and 
pharmacokinetics studies, might be ideal to do as further investigation of its 
feasibility as medication. Learning from experiences, if the amount of samples is 
plenty, it is advisable to sieve the samples after the synthesis. It will give more 
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uniform size of particle for the characterisations, especially for DVS and dissolution 
test. This way, the size uniformity is ensured, and it will complement the particle size 
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Appendix C: PXRD pattern of C:HC 1:1 from GAS and 
SADS methods  
 
 
Figure C.1. PXRD patterns of sample C:HC 1:1 obtained from supercritical CO2 GAS (gas 




Appendix D: TGA of C:HC mechanochemical samples   
 
Figure D.1. Thermogram of the mixed composition samples from mechanochemical 
synthesis. 
 
Mechanochemically made samples showed no weight loss until about 200 °C, and 
they began to decompose. This confirms that those samples are dry. They are neither 
hydrates nor solvates. Sample C:HC 1:2 starts to lose weight earlier than the rest of 
the sample. At 400 °C, the pure compounds lose more weight compare to the mixed 
composition samples. 
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Appendix E: DSC of C:HC mechanochemical samples   
 
Figure E.1. DSC of the mixed composition samples from the mechanochemical synthesis 
 
Sharp endotherm peak was observed, at about 223 °C for hydrocortisone and 229 °C 
for cortisone, which correspond to their respective melting points. The cortisone had 
a small exothermic peak at 207 °C prior to its endotherm peak. The mixed ratios 
samples from mechanochemical synthesis had broader endotherm peaks at a lower 
temperature compared to hydrocortisone and cortisone, with noticeable shoulders in 
samples C:HC 1:1 and 2:1. The absences of a single melting point and the lower peak 
temperature support the notion that mechanochemically made samples were mixtures 
instead of solid solutions.  
 
